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1 Introduction 
 
1.1 Cannabinoid receptors 
 
Cannabinoid receptors have been of high interest since their discovery in the early 
1990`s. In 1990, the first cannabinoid receptor mainly expressed in the central 
nervous system, named CB1R, was cloned (Matsuda et al., 1990). The CB1R is 
primarily located on presynaptic axon terminals in neurons and has an especially 
high density in the brain compared to other GPCRs. Apart from neurons, the CB1R is 
also present in the adrenal gland, bone marrow, heart, lung, prostate and testicles 
(Pertwee, 1997). Shortly after the discovery of CB1R, a second receptor, named 
CB2R, less highly expressed than the CB1R and mainly found in the periphery on 
immune cells and tissues was described (Munro et al., 1993). Particular high CB2R 
expression levels are found on B cells and natural killer cells (Howlett et al., 2002). 
Recently, CB2R have also been detected on neurons, but to a much lesser extent 
than the CB1R (Van Sickle et al., 2005; Gong et al., 2006). 
In 2006, an orphan receptor named GPR55 was highlighted as a putative CBR 
having similar signal transductory ways (Baker et al., 2006). GPR55 is activated by 
several cannabinoid receptor ligands. However, amino acid sequence homology to 
CB1R and CB2R is very low (Johns et al., 2007; Ryberg et al., 2007). Up to now it 
remains elusive, if there are more receptors belonging to the cannabinoid receptor 
group. 
Cannabinoid receptors belong to the family A of GPCRs with 7 transmembrane 
domains (TMD) and are Gαi/o protein-coupled. CBRs activate mitogen-activated 
protein kinases (MAPK), inhibit adenylyl cyclase activity after activation and are 
sensititve to pertussis toxin (Howlett, 2005). CB1R is also capable of inhibiting N-, 
P/Q- and L-type calcium channels in neurons and modulating potassium channels 
(Mackie et al., 1995; Twitchell et al., 1997). 
Aligning the amino acid sequence of both CBRs, they share only a 44% protein 
homology which increases to 68% compairing the TMDs (www.iuphar-db.org). The 
sequence identity in the TMDs is high enough that agonists, such as CP 55,940, 
anandamide and 2-AG, do bind to both subtypes (see Fig. 1 in Chapter 1.2.1). This 
may be explained by a similarity of their orthosteric ligand binding sites (Munro et al., 
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1993). The low overall sequence identity suggests the evolution of the different 
receptors very long ago in the past (McPartland and Glass, 2003). 
1.2 Cannabinoid receptor ligands 
 
1.2.1 Cannabinoid receptor agonists 
 
CBR agonists have very different chemical structures. Hence, they are often divided 
in 4 structural classes (see Fig. 1). First, the classic cannabinoids, e.g. ∆9-THC 
isolated from Cannabis sativa L. (var. indica), Cannabaceae. Second, the non-classic 
cannabinoids, e.g. CP 55,940, a Pfizer compound derived from ∆9-THC. In the third 
class are the endogenous cannabinoids, e.g. anandamide and 2-AG. The fourth 
class comprises the aminoalkylindoles, e.g. WIN 55,212-2. 
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WIN 55,212-2 mesylate 
 
Fig. 1: Examples for cannabinoid receptor agonists. 
1.2.2 Cannabinoid receptor antagonists/inverse agonists 
 
In general, CBR antagonists are not neutral antagonists, but inverse agonists. Those 
ligands can also be divided in different structural classes (see Fig. 2). CB1R 
antagonists/inverse agonists, e.g. AM 251 and AM 281, belong to the class of 
biarylpyrazoles. The CB2R antagonist/inverse agonist AM 630 belongs to the class of 
aminoalkylindoles. 
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Fig. 2: Examples for cannabinoid receptor antagonists/inverse agonists. 
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1.3 Endogenous ligands and endocannabinoid system 
 
Endogenous ligands for cannabinoid receptors, named endocannabinoids, have also 
been discovered. Up to now, two main endocannabinoids (EC) have been reported, 
anandamide (AEA), derived from the sanskrit word ananda for bliss, and                  
2-arachidonoyl glycerol (2-AG), for structures see Fig. 1 in Chapter 1.2.1 (Devane et 
al., 1992; Mechoulam et al., 1995; Sugiura et al., 1995). Those ligands are agonists 
at both receptors. However, AEA and 2-AG possess a 3 – 4 times higher affinity for 
the CB1R (Felder and Glass, 1998). Anandamide is also described as a partial 
agonist at both CBRs and can activate TRPV1 (vanilloid) receptors (Zygmunt et al., 
1999; Smart et al., 2000). The concentrations of endocannabinoids in the brain differ, 
2-AG is present in 50 – 500 fold higher concentrations than AEA (Felder et al., 1996; 
Sugiura et al., 2006). 
The endocannabinoid system (ECS) itself regulates many functions throughout the 
body, such as movement, memory, immune regulation, appetite and pain              
(De Petrocellis et al., 2004; Di Marzo et al., 2004). In general, imbalances in the ECS 
and the interaction of AEA and 2-AG result in various diseases, e.g. inflammation. 
Currently, neuroinflammatory disorders, such as Alzheimer`s disease, amyotrophic 
lateral sclerosis, multiple sclerosis, parkinson`s disease, are associated with 
malfunction of CBRs, because neurodegeneration is often linked to inflammatory 
processes (Centonze et al., 2007). 
Also, animal models of obese mice and Zucker rats showed elevated hypothalamic 
endocannabinoid levels. Endocannabinoid production was also increased in 
peripheral tissues, adipocytes, hepatocytes and pancreatic cells (Bensaid et al., 
2003; Cota et al., 2003; Pagotto et al., 2006). Targeting this overactivity of the ECS in 
obese animals led to the development of the first CB1R antagonist/inverse agonist 
SR141716A by Sanofi-Aventis (Meschler et al., 2000), named rimonabant 
(Acomplia®). Rimonabant was launched on the US and European market in 2005. 
However, severe neuronal side effects due to the blockade of CB1R in the brain, such 
as an increased risk for suicide, depression and fear, led to the withdrawal of the 
drug by the FDA in 2006. In Europe, the drug is still on the market, available for 
patients with a BMI > 30 or a BMI > 27 and other risk factors, such as diabetes     
type 2. However, intensive monitoring of these patients has to be performed and 
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patients with severe depressions are excluded from the treatment with rimonabant 
(www.emea.europa.eu). 
Just very recently, Merck developed taranabant (MK-0364), also a selective inverse 
agonist at CB1R. Taranabant is currently investigated in a phase III clinical study with 
2400 obese patients (Fong et al., 2007; Addy et al., 2008; Addy et al., 2008a). 
While CB1R antagonists are currently linked to the treatment of obesity, a drug 
already on the market and a second drug in the clinical stage, the development of 
clinically useful CB2R antagonists is still ongoing. However, CB2R antagonists are 
thought to be antiinflammatory and antiallergic drugs due to their localization on cells 
and tissues of the immune system. 
Agonists for cannabinoid receptors are also of high interest and intensive research is 
performed. After activation of CB1R by endogenous or exogenous agonists 
anticonvulsive effects and neuroprotective effects have been observed during 
ischemia and after traumatic brain injury (Panikashvili et al., 2001; Marsicano et al., 
2003). The connection of cannabinoids and pain is currently investigated (Lever and 
Rice, 2007). Stimulation of CB1R by exogenous cannabinoids on nociceptive neurons 
results in analgesia. Also, during stress, neuropathic conditions and inflammation, 
endocannabinoids are released modulating pain and nociception (Jhaveri et al., 
2007). 
Yet, continuous administration of CB1R agonists always led to tolerance and 
addiction in animals and humans (Maldonado, 2002; Justinova et al., 2005). 
Interestingly, activation of CB2R also had analgesic and antinociceptive effects 
(Ibrahim et al., 2003; Malan et al., 2003). The treatment of pain by CB2R and not 
CB1R agonists would result in less severe or even no neuronal side effects due to the 
much lower expression of CB2R in the CNS. 
1 Introduction 
 
6
1.4 Activation of GPCRs 
 
If a ligand binds to the receptor binding site, the conformation of the GPCR changes 
and G-protein (inactive state) couples to the receptor. The inactive G-protein 
heterodimer consists of a Gα-subunit, a Gβγ heterodimer and GDP bound to the Gα-
subunit. After binding and activation of the receptor by an agonist, the receptor binds 
to the heterotrimeric G-protein. GDP is then released from the Gα-protein and a 
ternary complex consisting of the agonist-occupied receptor and the nucleotide-free 
Gα forms. Subsequently, GTP binds to Gα. This GDP/GTP exchange causes a 
decrease in affinity of the Gα-subunit to the Gβγ heterodimer and the ternary complex 
is disrupted by disscociation in Gα-GTP and Gβγ. The separated Gα- and Gβγ- 
subunits can interact with effector proteins and continue the signal cascade. Due to 
the intrinsic GTPase activity of the Gα-subunit, GTP is hydrolysed to GDP and Pi. 
After the cleavage of Pi, the Gα- and Gβγ-subunit reassociate and the heterotrimer is 
ready to interact with another activated receptor. For illustration see Fig. 3. 
The intrinsic GTPase activity of the Gα-subunit, that means the hydrolysis of GTP 
bound to Gα to GDP and Pi, can be accelerated by RGS-proteins (regulators of G-
protein signaling). Hence, the reassociation of Gα/GDP- and Gβγ-subunits occurs 
faster, terminating the activation. This standard model of GPCR activation assumes 
that the lifetime of Gα-GTP and the hydrolysis of GTP is the rate-determining step of 
the signaling process. 
In the steady-state GTPase assay, a radioactively labeled GTP derivative is used.   
[γ-32P]GTP binds to the Gα-subunit and is then hydrolysed to GDP and radioactive 
32Pi by the intrinsic GTPase activity of Gα. The amount of released 32Pi is measured 
under steady-state conditions (usually 20 min) and can be determined by liquid 
scintillation counting. 
The GTPγS binding assay kinetically determines the GDP/GTP exchange at the     
Gα-subunit. In contrast to [γ-32P]GTP, [35S]GTPγS cannot be hydrolysed by the Gα-
subunit and the heterotrimeric G-protein accumulates. This assay can be performed 
as a filtration assay through glass-fibre filters, as the Gα-subunit/[35S]GTPγS complex 
remains membrane-associated and is not filtrated. [35S]GTPγS on the filters can also 
be determined by liquid scintillation counting (Harrison and Traynor, 2003). 
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Fig. 3: Mechanism of G-protein activation of GPCRs by ligands and possible methods 
to analyse GPCRs by radioactively labeled GTP derivatives (Seifert and Wenzel-
Seifert, 2003). 
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1.5 Two-state activation model of GPCRs 
 
According to the two-state model of GPCR activation (Leff, 1995), a receptor can 
exist in two states, the active state R* and the inactive state R. Both states, R* and R, 
are in equilibrium. R* can bind G-proteins, as described in Chapter 1.4, whereas R 
does not interact with G-proteins, and no GDP/GTP exchange will happen. 
Depending on the pharmacological profile of ligands, the different states of the 
receptor will be stabilized and hence the equilibrium can be shifted to one side (see 
Fig. 4). Agonists stabilize the active conformation R* of the receptor, whereas inverse 
agonists stabilize the inactive form R of the receptor. Neutral antagonists do not alter 
the equilibrium between R* and R, but occupy the binding site of other ligands at the 
GPCR. Actually, many neutral antagonists are inverse agonists. Though inverse 
agonists stabilize the inactive state R, some of the receptors remain in the active 
state R* with no agonist bound due to the present equilibrium. This fact is called 
constitutive activity. Constitutive activity is often observed among GPCRs, e.g. the 
formyl peptide receptor (Seifert and Wenzel-Seifert, 2003) and might also be related 
to diseases (Seifert and Wenzel-Seifert, 2002). 
 
 
 
Fig. 4: Two-state activation model of GPCRs. Agonists stabilize the active conformation 
R*, inverse agonists the inactive conformation R and antagonists do not alter the equilibrium 
between the two states of the receptor (Seifert and Wenzel-Seifert, 2002). 
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According to the model, full agonists generate full receptor activation and a maximal 
response (Emax = 100%). Partial agonists result in a sub-maximal response due to a 
lower intrinsic efficacy. They also might attenuate a maximal response produced by a 
full agonist. Antagonists result in no physiological response at all. 
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1.6 Plant-derived ligands at CBRs 
 
Decades before the two cannabinoid receptors CB1R and CB2R were cloned,         
∆9-THC and other cannabinoids were isolated of C. sativa L. and their structures 
were elucidated (Mechoulam and Gaoni, 1965). Most of the compounds do bind to 
CBRs, e.g. ∆9-THC, ∆8-THC and cannabinol. Others, e.g. cannabidiol, do not 
(Ashton, 2001). All above noted compounds are depicted in Fig. 5. 
 
 
O
OH
  O
OH
 
∆9-THC       ∆8-THC 
 
 
O
OH
  HO
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Cannabinol      Cannabidiol 
 
Fig. 5: Structures of compounds isolated from C. sativa. 
 
 
Just recently, the immunomodulatory effects of Echinacea species have been linked 
to cannabinoid receptors, indicating the first natural ligands at CBRs not derived from 
C. sativa (Gertsch et al., 2004; Woelkart et al., 2005). 
It has been reported that an extract of Echinacea purpurea (Echinaforce®) showed an 
induction of the de novo synthesis of TNFα mRNA, but not TNFα protein, in human 
monocytes and macrophages. Lipophilic compounds with a high structural similarity 
to the known endogenous cannabinoid receptor ligands anandamide and 2-AG have 
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been proposed to be responsible for the TNFα mRNA synthesis (Gertsch et al., 
2004). This class of plant compounds is named alkamides, a shorter version of the 
name alkylamides. CB2R are mainly found in the periphery and are expressed on 
immune cells, such as monocytes and macrophages (Klein et al., 2003), and the 
endogenous CBR agonists anandamide and 2-AG inhibit the release of TNFα by 
immune cells (Chang et al., 2001). Hence, Gertsch et al. reported that alkamides 
may activate cannabinoid receptors. They showed that the induction of TNFα mRNA 
synthesis was blocked only by selective CB2R antagonists and not by selective CB1R 
antagonists (Gertsch et al., 2004). 
The compounds which have been described as CB2R agonists are the isomer pair 
dodeca-2E,4E,8Z,10E-tetraenoic acid isobutylamide and dodeca-2E,4E,8Z,10Z-
tetraenoic acid isobutylamide, dodeca-2E,4E,8Z-trienoic acid isobutylamide and 
dodeca-2E,4E-dienoic acid isobutylamide (see Fig. 6). 
Dodeca-2E,4E,8Z,10Z-tetraenoic acid isobutylamide and dodeca-2E,4E-dienoic acid 
isobutylamide interacted with the CB2R in a homology model based on the crystal 
structure of bovine rhodopsin. The amphiphilic property of these alkamides allowed 
docking in the predicted binding pocket of the CB2R. Both alkamides showed even 
higher affinity at the human CB2R than anandamide in radioligand displacement 
studies (Raduner et al., 2006).  
Alkamides isolated from the roots of E. angustifolia also have been screened for rat 
CB1R and mouse CB2R affinity in a [3H]CP 55,940 competition binding assay 
(Woelkart et al., 2005). Several alkamides showed affinities for cannabinoid 
receptors in the micromolar range, but none of the depicted compounds by Gertsch 
et al. (Fig. 6) showed selectivity for either CB1R or CB2R (Woelkart et al., 2005). 
Contradictory results as pointed out above have been linked to the history of 
Echinacea since research in this field started. 
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isobutylamide     isobutylamide 
 
Fig. 6: Alkamides isolated from E. purpurea described as CB2R agonists (Gertsch et 
al., 2004). 
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1.7 Use of Echinacea 
 
Echinacea has been already used in the 18th and 19th century by the Indians of 
North America for the treatment of wounds, burns, toothache and common cold. 
Several classes of compounds, such as caffeic acid derivatives, flavonoids, 
polyacetylenes, alkamides, pyrrolizidine alkaloids, polysaccharides and glycoproteins 
have been isolated from Echinacea species (Bauer and Wagner, 1990; Hostettmann, 
2003). The genus Echinacea Moench (Heliantheae: Asteraceae) consist of four 
species, which probably belong to eight varieties. Three different taxa are cultivated 
and used for medical purposes: E. purpurea (L.) MOENCH, E. pallida var. angustifolia 
(DC.) CRONQ. and E. pallida var. pallida (Nutt.) CRONQ. (Binns et al., 2002a). Apart 
from the above described class of alkamides, other more hydrophilic compounds 
have been reported being responsible for the immunomodulatory effects, such as the 
caffeic acid derivates (see Fig. 7) or polysaccharides/glycoproteins (Bauer, 1999; 
Classen et al., 2004). 
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Fig. 7: Examples for hydrophilic caffeic acid derivates in Echinacea. 
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Caffeic acid derivates are mainly considered to be responsible for the antioxidative 
effects of Echinacea preparations (Xiong et al., 1996; Heilmann et al., 2000). 
However, echinacoside also decreased the NO concentration in rat macrophages 
which may contribute for the antiinflammatory effects of Echinacea (Xiong et al., 
2000). Several polysaccharides and glycoproteins isolated from E. purpurea and 
E. angustifolia showed immunomodulatory effects, e.g. an increased phagocytotic 
activity (Wagner et al., 1985) or a proliferative effect on rat spleen cells (Beuscher et 
al., 1995). 
Interestingly, alkamides are not present in all Echinacea species, e.g. in E. pallida. 
However, E. pallida roots contain another class of lipophilic compounds which can 
only be found in this Echinacea species (see Fig. 8). Those ketoalkenes and 
ketoalkynes are present in the whole plant. They are also components of the 
essential oil of the roots of E. pallida. Approximately half of the essential oil consists 
of only two compounds, pentadec-8Z-en-2-one and pentadeca-1,8Z-dien. Although 
ketoalkenes and ketoalkynes show structural similarity to the endocannabinoid 
anandamide, those compounds and E. pallida in general have never been analysed 
for their immunological activity. 
 
O
   
O
 
 
Pentadeca-8Z,13Z-dien-11-yn-2-one       Pentadeca-8Z,11Z,13E-trien-2-one 
 
O
O
 
 
Pentadec-8Z-en-2-one         Tetradeca-8Z-en-11,13-diyn-2-one 
 
Fig. 8: Overview of ketoalkenes and ketoalkynes present in E. pallida roots. 
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The use of Echinacea for the treatment of common cold has been topic of many 
clinical trials and scientific publications, often with contradictory outcome. It is known 
that different manufacturers and different batches of the same plant extract lead to 
large differences in the concentrations of active or adjuvant compounds (Osowski et 
al., 2000). This reflects the main disadvantage of especially older studies, no 
quantification of the potentially active compounds was made and sometimes not 
even the investigated species or plant material were defined correctly. Some clinical 
trials were not performed according to GCP guidelines, e.g. patient population was 
inhomogenous, only a small number of patients was included or the dosage scheme 
did not meet actual standards (Melchart et al., 1995; Melchart et al., 1998; Schwarz 
et al., 2005). 
Until now, the following species and plant parts have been used for clinical trials on 
Echinacea-containing drugs: preparations of E. purpurea herb, roots and herb with 
roots, E. pallida and E. angustifolia roots. Of 13 randomized double-blind studies 
treating infections of the upper respiratory tract, 6 studies showed a significantly 
better outcome when patients used an Echinacea-containing drug. However, the 
drugs used in the 3 latter studies had a relatively low or not detectable alkamide or 
cichoric acid content (Osowski et al., 2000). Most of the modern clinical studies 
according to GCP guidelines prove the efficacy using Echinacea to reduce the 
incidence and duration of the common cold (Goel et al., 2004; Shah et al., 2007). 
On the molecular pharmacological level, the antiinflammatory and antifungal activity 
of Echinacea species has been widely investigated (Müller-Jakic et al., 1994). 
Regarding the antiviral activity against herpes simplex virus (HSV-1), lipophilic         
n-hexane root extracts containing alkamides were more active than more hydrophilic 
ethyl acetate extracts containing caffeic acids (Binns et al., 2002).  
Despite the popularity of Echinacea containing herbal products, especially on the 
U.S. market, the underlying molecular mechanisms remain unclear and poorly 
understood. 
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2 Scope and Objectives 
 
G-protein coupled receptors (GPCRs) represent the largest group of transmembrane 
receptors. GPCRs are often related to diseases and have therefore been of high 
interest for the last decades. About 50% of the drugs on the market target GPCRs 
and among all top-selling drugs more than one third are ligands of GPCRs (Nambi 
and Aiyar, 2003). Hence, it is not only very important for pharmacological but also 
interesting for financial reasons for pharmaceutical companies to find new ligands for 
GPCRs, especially for those which are only known for a short time, such as 
cannabinoid receptors. 
 
It is also necessary to evaluate the efficacies and pharmacological profiles of GPCR 
ligands. Competition binding assays with a radiolabeled ligand and increasing 
concentrations of the investigated compound are often applied. However, this assay 
does not allow the differentiation of full or partial agonists, inverse agonists and 
antagonists. Other test systems measure the effects at a very distal point of the 
signal cascade via second messengers, e.g. the increase of intracellular Ca2+ levels 
by FACS or the measurement of cAMP concentrations. These second messengers 
are often influenced by receptor-independent effects. Therefore, determination of the 
release of 32Pi in the GTPase assay or the GDP/GTP exchange in the GTPγS binding 
assay is more suitable. 
 
Only a few years ago, alkamides of E. purpurea have been proposed to be ligands at 
CB2R (Gertsch et al., 2004; Woelkart et al., 2005). However, alkamides have only 
been characterized as ligands in competition binding assays. The fact that a 
compound binds to a receptor or is able to compete with another compound bound to 
a receptor does not automatically demonstrate pharmacological activity. Also, 
Echinacea preparations that are efficient treating common cold do not always contain 
E. purpurea, but also E. pallida. The latter possesses ketoalkenes and ketoalkynes, 
which are very lipophilic compounds and are only present in E. pallida. Those 
compounds have neither been discussed as possible ligands nor been tested for 
CBR affinity at all. 
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Therefore, our interest was to establish several functional assays to study 
cannabinoid receptors and their ligands at a proximal point of the signal cascade, 
such as the steady-state GTPase assay and the GTPγS binding assay. We also 
wished to optimize [3H]CP 55,940 competition binding assay to complete 
pharmacological investigations characterizing cannabinoid receptor ligands. The 
effects of different Gα-subunits, RGS-proteins and solvents should be investigated. 
We were further interested if differences in the coupling and activation of CBR via 
Gα-proteins exist. 
 
In summary, the aim of this thesis was to establish several highly sensitive and 
efficient test systems to fully characterize cannabinoid receptors, to detect 
pharmacological properties of commercially available ligands and to analyse isolated 
natural and synthesized ligands derived from Echinacea species by functional test 
systems. 
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3 Materials and Methods 
 
3.1 Pharmacological materials 
 
The cDNA for hCB1R and hCB2R in pcDNA 3.1 was obtained from the cDNA bank of 
the University of Missouri (Rolla, MO, USA). All restriction enzymes and T4 ligase 
were from New England Biolabs (Beverley, MA, USA). Cloned Pfu DNA polymerase 
was from Stratagene (La Jolla, CA, USA). The anti-FLAG Ig (M1 monoclonal 
antibody) was from Sigma (St. Louis, MO, USA). The anti-Gαi common Ig, anti-Gβcommon 
Ig, purified Gαi- and Gβ1γ2-protein were a kind gift from Dr. Dr. B. Nürnberg 
(Department of Biochemistry, University of Düsseldorf, Germany). The anti-CB Igs 
and the anti-Gαo Ig were from Calbiochem (La Jolla, CA, USA). Antibodies for RGS- 
and GAIP-protein were obtained by Santa Cruz Biotechnology Inc. (Santa Cruz, CA, 
USA). Baculovirus encoding for Gαo was a kind gift by Dr. J. Garrison (University of 
North Carolina, Chapel Hill, NC, USA). Baculovirus encoding Gαi2 was generously 
provided by Dr. A. G. Gilman (Department of Pharmacology, University of Texas 
Southwestern Medical Center, Dallas, TX, USA). Baculovirus encoding Gβ1γ2 was a 
kind gift from Dr. P. Gierschik (Department of Pharmacology, University of Ulm, 
Germany). Baculoviruses encoding for RGS4 and GAIP were a kind gift from          
Dr. E. Ross (University of Texas Southwestern Medical Center, Dallas, TX, USA). 
Phenylmethylsulfonylfluoride and leupeptine hemisulfate were from Calbiochem     
(La Jolla, CA, USA). Benzamidine 99% was from Sigma-Aldrich (St. Louis, MO, 
USA). Adenylyl imidophosphate (AppNHp) was obtained from Roche (Mannheim, 
Germany). Boric acid p.A. was from Merck (Darmstadt, Germany). 
[3H]CP 55,940 (160 Ci/mmol), [35S]GTPγS (1,100 Ci/mmol) and [α-32P]ATP 
(3,000 Ci/mmol) were from PerkinElmer Life Sciences (Boston, MA, USA).                
[γ-32P]GTP was synthesized through enzymatic phosphorylation of GDP and 
[32P]orthophosphoric acid (8,000 Ci/mmol, PerkinElmer Life Sciences, Boston, MA, 
USA) as described previously (Walseth and Johnson, 1979). Mono(cyclohexyl)-
ammoniumphosphoenolpyruvate, pyruvate kinase and myokinase were from Sigma 
(St. Louis, MO, USA). 
Unlabeled GTPγS, all nucleotides, creatine kinase, creatine phosphate, 
polyethyleneimine solution (50% (w/v) in water), glucose and salts (highest purity 
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available) were purchased either from Roche (Mannheim, Germany) or Sigma       
(St. Louis, MO, USA). Forskolin was purchased from LC laboratories (Woburn, MA, 
USA). Dimethyl sulfoxide and glycerol were from Merck (Darmstadt, Germany). Tris 
base was purchased from USB (Cleveland, OH, USA). GF/C filters were from 
Brandel (Gaithersburg, MD, USA). Agarose was purchased from Biozym Scientific 
(Oldendorf, Germany). Ethidium bromide (10 mg/ml) was from Sigma (St. Louis, MO, 
USA). Ampicillin was from Fisher BioReagents (Fisher Scientific, Schwerten, 
Germany). 
The CBR ligands CP 55,940, anandamide, 2-AG, WIN 55,212-2, AM 251 and 
AM 630 were purchased from Tocris Cookson (Ballwin, MO, USA). ∆9-THC was 
obtained by THC Pharm (Frankfurt/Main, Germany). 
 
3.2 Buffers and media 
 
For the preparation of buffers and solutions Millipore water was used, unless 
otherwise stated. DEPC water was prepared by adding 1 ml DEPC ad 1 l Millipore 
water and autoclaving the solution the following morning. 
For Sf9 cell culture, SF 900 II medium (Invitrogen, Carlsbad, CA, USA) was 
supplemented with fetal calf serum (Pan-Biotech, Aidenbach, Germany) to 5% (v/v) 
and gentamicin sulfate (BioWhittaker, Walkersville, MD, USA) to 0.1 mg/ml. 
 
LB medium (pH = 7.0) 
10 g NaCl 
10 g tryptone (Difco, Detroit, USA) 
5 g yeast extract (Roth, Karlsruhe, Germany) 
ad 1000 ml Millipore water (pH=7.0) 
 
selective LB medium 
add 100 mg/l ampicillin to sterilized LB medium 
 
selective agar plates 
add 20 g Agar (Roth, Karlsruhe, Germany) per l of LB medium 
sterilize, let medium cool down to 55 – 60°C, add 100 mg/l ampicillin 
store agar plates at 4°C 
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SOC medium 
add to LB medium  
2.5 mM KCl 
10 mM MgCl2 
10 mM Mg2SO4 
add 20 mM glucose after sterilization 
 
PBS buffer (pH = 7.4) 
137 mM NaCl 
2.6 mM KCl 
0.5 mM MgCl2 
0.9 mM CaCl2 
1.5 mM KH2PO4 
0.8 mM Na2HPO4 
 
Lysis buffer (pH = 7.4) 
10 mM Tris/HCl 
1 mM EDTA 
0.2 mM phenylmethylsulfonylfluoride  
10 µg/ml benzamidine 
10 µg/ml leupeptin 
 
Binding buffer (pH = 7.4) 
75 mM Tris/HCl 
1 mM EDTA 
12.5 mM MgCl2 
 
TBE buffer 
89 mM Tris-base 
89 mM boric acid 
2 mM EDTA 
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3.3 Pharmacological methods 
 
3.3.1 Sf9 cell/baculovirus expression system 
 
Sf9 cells, derived from Spodoptera frugiperda pupal ovarian tissue, are commonly 
used for baculovirus expression. Insect cells do not possess mammalian GPCRs or 
G-proteins; hence by coinfection of baculoviruses encoding for a certain GPCR and 
for the needed G-proteins functional studies of GPCRs can be performed (Wenzel-
Seifert and Seifert, 2003). Insect cells can be grown rather easily and do not require 
a CO2 atmosphere. The Sf9 cell/baculovirus expression system itself offers several 
advantages, such as high GPCR expression (up to 30 pmol/mg), high G-protein 
expression (up to 500 pmol/mg), large yields of protein and easy reconstitution of 
GPCRs and G-proteins. Possible disadvantages of this system could be misfolding or 
proteolysis of expressed proteins. Also, the N-glycosylation of GPCRs by insect cells 
is different from mammalian cells. 
 
 
3.3.2 Transformation of CB1 and CB2 receptor DNA in E. coli 
 
100 µl of competent E. coli (JM109) were thawed on ice and 2 ng of the DNA (in 
10 mM Tris/HCl, pH 8.5) were added and very gently mixed. After 30 min of 
incubation on ice the suspension was heated to 42°C for 60 sec and placed on ice for 
3 min. 900 µl of SOC medium was added and the mixture was incubated for 60 min 
at 37°C under shaking at 200 rpm in an incubation shaker (New Brunswick Scientific, 
model C24KC, Edison, NJ, USA). Then, 100 µl of the incubated suspension was 
plated on selective agar containing 0.01% (m/v) ampicillin. The plates were incubated 
overnight at 37°C to grow ampicillin-resistant colonies. The next morning, 2 - 6 
colonies were picked, placed in selective LB medium (2.5 ml for MiniPrep, 100 ml for 
MaxiPrep). Small amounts of DNA (up to 20 µg) were isolated for analytical purposes 
(MiniPrep), whereas larger amounts of DNA (up to 500 µg) were isolated for 
transfection (MaxiPrep). For both preparations the Qiagen Plasmid Purification Kit 
(Qiagen, Hilden, Germany) was used according to the instructions of the 
manufacturer. Glycerol stocks of MaxiPrep cultures were prepared (700 µl bacterial 
suspension and 300 µl glycerol 50%) and stored at -80°C. 
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3.3.3 DNA analytics 
 
3.3.3.1 Electrophoretic separation of DNA on agarose gels 
Agarose gels were prepared by dissolving 1 – 2% (w/v) agarose in TBE buffer under 
heating. 4 µl ethidium bromide solution (10 mg/ml) was added to the warm mixture 
before pouring it in the gel chamber. After cooling down, gels were covered with TBE 
buffer. DNA samples were mixed with loading dye, pipetted in the pockets of the gel 
and separated by applying a voltage of 150 V for 30 min. An appropriate DNA 
molecular weight standard was used (GeneRulerTM, Fermentas, St. Leon-Rot, 
Germany). Due to intercalation of the DNA with ethidiumbromide gels could be 
analysed at UV-light radiation at 254 nm (BDA Digital, Biometra, Göttingen, 
Germany). 
For preparative electrophoresis or purifying PCR-products with subsequent extraction 
of DNA, 1% (w/v) agarose gels were used. After separation, DNA fragments were cut 
out of the gel at a higher wavelength (366 nm) to avoid mutations or strand breaks. 
To elute the DNA of the agarose gel the Qiagen PCR Purification Kit (Qiagen, Hilden, 
Germany) was used according to the instructions of the manufacturers. DNA 
concentrations were determined (DC protein assay kit, BioRad, Hercules, CA, USA) 
and DNA was stored at -20°C until use. 
 
3.3.3.2 Restriction analysis of DNA and gene sequencing 
Various enzymes (New England BioLabs, Frankfurt, Germany) were used for 
restriction analysis of the DNA (see Chapter 3.3.4). Usually, double digests were 
carried out by mixing 1 µg of DNA with 1 µl of each restriction enzyme and 1.5 µl of 
the according buffer. Millipore water and, if necessary, BSA solution were added to a 
final volume of 15 µl. After incubation at 37°C for 90 min, an inactivation step was 
carried out by heating the mixture to 65°C for 15 min. Electrophoretic analysis of the 
DNA was performed after adding loading buffer to each sample as described above. 
Sequences were determined by Entelechon (Regensburg, Germany) using 
fluorescence dye-labeled stop nucleotides. Gene sequences were analysed with 
pDRAW 3.2 (AcaClone software) and Gene Runner 3.05 software (Hastings 
Software, New York, USA). 
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3.3.4 Construction of FLAG epitope- and hexahistidine-tagged hCB1R and 
hCB2R 
 
The cDNA for hCB1R and hCB2R in pcDNA 3.1 was obtained from the cDNA bank of 
the University of Missouri (Rolla, MO, USA) on filter paper. The plasmid was 
reconstituted by elution for 4 h at 4°C with 50 µl 10 mM Tris/HCl, pH 8.5. After 
centrifugation for 1 min at 18.000 x g, the supernatant containing the eluted DNA was 
collected and used directly for the transformation of competent E. coli (JM109). The 
concentration of isolated DNA by MaxiPrep was determined and then analysed on 
agarose gels. 
hCBR constructs were generated by analogy to the previously described strategy 
(Wenzel-Seifert et al., 1999; Wenzel-Seifert and Seifert, 2000; Seifert and Wenzel-
Seifert, 2001). By sequential overlap-extension PCR, a DNA sequence encoding the 
cleavable signal peptide from influenza hemagglutinin to direct the receptor protein to 
the cell membrane, followed by the FLAG epitope, which is recognized by the M1 
monoclonal antibody, was placed 5` of the start codon of the cDNA of the hCBRs. 
3` of the cDNA a hexahistidine (6xHIS) epitope to allow further purification was 
introduced. 
In PCR 1A with pGEM-3Z-SFhH4R as template, a DNA fragment consisting of a SacI 
restriction site, the signal peptide (S) and the FLAG epitope (F) was amplified (see 
Fig. 9). The sense primer F1 annealed prior to the 5` end of SF of pGEM-3Z, 
containing a SacI restriction site. The antisense primer C3 encoded                     
5`-CATGGCGTCATCATCGTC-3` annealing at the 3` end of the FLAG epitope 
sequence. All primers were synthesized by MWG-Biotech (Ebersberg, Germany), for 
sequences see Table 1. PCR was performed with a T1-Thermocycler (Biometra, 
Göttingen, Germany). The PCR 1A and 1B tubes were prepared by mixing 5 µl 
1 mM dNTP-mix (Promega, Madison, WI, USA), 10 µl Pfu reaction buffer, 1 µl Pfu 
DNA polymerase solution (2.5 U/µl), 10 µl DMSO, 5 µl of sense and antisense primer 
(10 µM), 1 µl DNA (0.1 µg/µl) and 63 µl DEPC-water.  
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Fig. 9: Generation of the PCR 1A product. 
 
In PCR 1B, a part of the FLAG epitope, the DNA sequence of hCB1R or hCB2R and a 
hexahistidine tag was generated (see Fig. 10). The sense primer encoded the 
sequence 5`GACGATGATGACGCCATGAAGTCGATCCTAGATGG-3`(hCB1R) or  
5`-ACGATGATGACGCCATGGAGGAATGCTGGGTG-3` (hCB2R). The antisense 
primer annealed with the cDNA encoding the 5 C-terminal amino acid residues of 
hCB1R/hCB2R, the stop codon and an XbaI site (hCB1R) or a PstI site (hCB2R). 
 
 
Fig. 10: Generation of the PCR 1B product. 
  SacI 
Signal peptide 
       F1 - Primer 
       C3 - Primer 
FLAG 
CBxR
XbaI / PstI
CBxR_rev - Primer 
CBxR_for - Primer 
pcDNA3.1-CBxR
3 Materials and Methods 
 
25
 
PCR 1A and 1B were performed using the following program: 
 
1. 5 min   95°C 
2. 1 min   95°C 
3. 1 min   53°C 
4.  1 min (PCR 1A) 72°C 
 2 min (PCR 1B) 72°C 
5. 10 min  72°C 
6.  hold   4°C 
Steps 2. – 4. were repeated 25 times. 
 
 
In PCR 2, the products of PCR 1A and 1B annealed in the region of the FLAG 
epitope using the primers F1 and CBxR_rev, the respective reverse primer (see 
Fig. 11). 
The PCR 2 tube was prepared by mixing 5 µl 1 mM dNTP-mix (Promega, Madison, 
WI, USA), 10 µl Pfu reaction buffer, 1 µl Pfu DNA polymerase solution (2.5 U/µl),    
10 µl DMSO, 5 µl of sense and antisense primer (10 µM), 1.5 µl PCR 1A and 1.5 µl 
PCR 1B product and 61 µl DEPC-water. Polymerase chain reaction was performed 
using the same program as described above. 
 
 
 
Fig. 11: Structure of the hCBxR construct after PCR 2. 
 
 
The product of PCR 2 and pGEM-3Z-SFhH4R were digested with SacI and XbaI 
(hCB1R) or SacI and PstI (hCB2R). Both double digested mixtures were 
electrophoretically separated on a preparative agarose gel. The expected bands 
were cut out of the gel and purified by the Qiagen PCR Purification Kit (Qiagen, 
Hilden, Germany). For the ligation of the hCBxR construct and the pGEM-3Z-SFhH4R 
SacI FLAG 6xHIS Signal peptide CBxR
XbaI / 
PstI 
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vector, an insert to vector ratio of 3:1 was used. cDNAs for FLAG- and hexahistidine-
tagged hCB1R and hCB2R were then cloned into the baculovirus transfer vector 
pVL1392 for transfection of Sf9 insect cells. PCR-generated DNA sequences were 
confirmed by extensive restriction enzyme analysis and enzymatic sequencing. 
 
 
Table 1: Primer sequences used for overlap-extension PCR. 
 
Primer Sequence 
F1 (sense) 5`-GCT CAC TCA TTA GGC ACC-3` 
 
C3 (antisense) 5`-CAT GGC GTC ATC ATC GTC-3` 
 
CB1_for (sense) 5`-GAC GAT GAT GAC GCC ATG AAG TCG ATC CTA GAT GG-
3` 
 
CB1_rev (antisense) 5`-AAT TCT CTA GAG GTC ACA GAG CCT CGG CAG ACG-3` 
 
CB2_for (sense) 5`-GAC GAT GAT GAC GCC ATG GAG GAA TGC TGG GTG-3` 
 
CB2_rev (antisense) 5`-TGG GCT GCA GTC AGT GAT GGT GAT GAT GGT GGC 
AAT CAG AGA G-3` 
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3.3.5 Generation of recombinant baculoviruses, cell culture and membrane 
preparation 
 
Recombinant baculoviruses encoding FLAG- and hexahistidine-tagged hCB1R and 
hCB2R were generated in Sf9 cells using the BaculoGOLD transfection kit             
(BD PharMingen, San Diego, CA, USA) (Wenzel-Seifert et al., 1999; Wenzel-Seifert 
and Seifert, 2000; Seifert and Wenzel-Seifert, 2001). After initial transfection,      
high-titer virus stocks were generated by two sequential virus amplifications. In the 
first amplification, cells are seeded at 2.0 x 106 cells/ml and infected with a 1:100 
dilution of the supernatant of the culture following initial transfection. 7 days after the 
transfection, all cultured cells died releasing virus to the medium. Efficient 
transfections can be observed visually because infected cells change their 
morphology from round cells forming a confluent monolayer to enlarged or lysed cells 
(see Fig. 12). The virus containing supernatant of the first amplification, was 
harvested by centrifugation for 10 min at 3,000 x g. The obtained supernatant was 
used in a 1:20 dilution for the second amplification, where cells are seeded at         
3.0 x 106 cells/ml. After 48 h, the supernatant was harvested as described above. 
Cells showed signs of infection but not all cells were lysed after 48 h. The 
supernatant of the second amplification was used for all further transfections and 
membrane preparations. All supernatants containing baculoviruses were stored at 
4°C and, if protected from light, can be kept for up to 5 years without loss of potency. 
 
 
Fig. 12: Uninfected Sf9 cells (A) and Sf9 cells after transfection with recombinant 
baculoviruses (B), (adapted from Dr. A. Gille). 
 
A B
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Generally, Sf9 cells were cultured in 250 ml disposable Erlenmeyer flasks at 28°C 
shaking at 125 rpm in an incubation shaker (New Brunswick Scientific, model 
C24KC, Edison, NJ, USA) in SF 900 II medium supplemented with fetal calf serum to 
5% (v/v) and gentamicin sulfate to 0.1 mg/ml. Supplementation of fetal calf serum is 
not absolutely necessary, but cells grow better and show higher GPCR expression 
levels if serum is added. Sf9 cells were maintained at a density of 0.5 to 6.0 x 106 
cells/ml. For transfection, cells were seeded at 3.0 x 106 cells/ml and infected with a 
1:100 dilution of high-titer baculovirus stocks encoding either hCB1R or hCB2R as 
well as Gαo- or Gαi2- and Gβ1γ2-protein. In some transfections, RGS4 or GAIP were 
additionally coexpressed. Cells were cultured for 48 h and checked for signs of 
infection before membrane preparation. Sf9 membranes were prepared as described 
previously (Wenzel-Seifert and Seifert, 2000). All membrane preparation steps were 
conducted at 4°C in 50 ml Falcon tubes. Briefly, cells were washed once by 
centrifuging for 10 min at 170 x g, discarding the supernatant and resuspending the 
cell pellet in 50 ml PBS-buffer. After repeating the centrifugation step, the 
supernatant was discarded and the pellet was suspended in 15 ml lysis buffer and 
homogenized in a 15 ml Dounce homogenizer with 25 strokes. After centrifugation at 
40 x g for 5 min the pellet contained the nuclei and unbroken cells and the 
supernatant contained the membranes. Therefore, the supernatant was carefully 
transferred to a plastic Sorvall tube and spun down by 38,500 x g for 20 min in a 
Sorvall centrifuge. The pellet containing the membranes was resuspended in 20 ml 
lysis buffer and again centrifuged as described above. The resulting membrane pellet 
was suspended in 25 ml binding buffer and homogenized by a syringe with 20 
strokes. Protein concentrations were determined using the DC protein assay kit 
(BioRad, Hercules, CA, USA) according to the instructions of the manufacturer. This 
assay allows the protein determination in presence of reducing agents or detergents 
and is based on a colorimetric reaction according to the Lowry method. 
The membrane suspension was aliquoted into 25 tubes at 1 ml each for storage at    
-80°C until use. At -80°C, GPCRs and G-proteins are functionally and structurally 
stable for up to 4 years. By SDS-PAGE and immunoblotting with specific antibodies 
the expression of FLAG-tagged cannabinoid receptors, G-protein subunits and RGS-
proteins was confirmed (see Chapter 4.1.1). 
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3.3.6 SDS-PAGE and immunoblot analysis 
 
Membrane proteins were separated on 0.1% (m/v) SDS polyacrylamide gels 
containing 12% (w/v) acrylamide at 110 V for 150 min (Wenzel-Seifert et al. 1999; 
Wenzel-Seifert and Seifert 2000; Seifert and Wenzel-Seifert 2001). Proteins were 
transferred onto Immobilon-P membranes (Millipore, Bedford, MA, USA) at 0.15 A for 
120 min at 4°C. Non-specific binding sites were blocked for 2 h before proteins 
reacted with specific antibodies, M1 antibody (1:1,000), CB1R or CB2R antibody (both 
1:1,000), anti-Gαo, anti-Gαi common, anti-RGS4, anti-GAIP Ig (all 1:500) or anti-
Gβcommon (1:2,000). Immunoreactive protein bands were visualized by enhanced 
chemoluminescence (Pierce, Rockford, IL, USA) using goat anti-mouse IgG for the 
M1 antibody, donkey anti-rabbit IgG for CB1R/CB2R, anti-Gα and anti-Gβ Igs; and 
donkey anti-goat IgG for anti-RGS4 and anti-GAIP Igs coupled to peroxidase. 
 
 
3.3.7 Handling of cannabinoid receptor ligands 
 
Almost all commercially available CBR ligands are highly lipophilic. Their solubility in 
water is very low, which implies dissolving them in aequous solutions, such as 
binding buffer, is not possible at all. However, solubility in DMSO or ethanol is 
sufficient to prepare at least 1 mM stock solutions. Ethanol has several 
disadvantages relative to DMSO. Firstly, ethanol evaporates easily, making it difficult 
to ensure accurate concentrations present in either stored stock solutions or 
dilutions. Secondly, ethanol is toxic for cell proteins, whereas DMSO can be used in 
concentrations up to 5% (v/v) in Sf9 cell membranes without affecting receptor 
protein function. 
Therefore, stock solutions of CBR ligands (10 mM each) were prepared in dimethyl 
sulfoxide and stored at -20°C for up to 3 months without loss of pharmacological 
activity. Dilutions of ligands were prepared in such a way that the dimethyl sulfoxide 
concentration was 30% (v/v) and that the final dimethyl sulfoxide concentration in all 
assay tubes was 3% (v/v). A final volume percentage of 3% DMSO assured accurate 
and stable solutions without affecting the receptor protein. Lowering the DMSO 
concentration to 1% (v/v) resulted in cloudy suspensions when diluting ligands. 
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Some CBR ligands, such as anandamide or ∆9-THC are oily and therefore presolved 
in ethanol. Therefore, ethanol was completely removed and compounds were 
subsequently dissolved in DMSO to obtain 10 mM stock solutions. 
 
 
3.3.8 [3H]CP 55,940 competition binding assay 
 
Membranes were thawed, sedimented by centrifugation at 18,000 x g for 10 min at 
4°C, and carefully resuspended in 10 mM Tris/HCl, pH 7.4. Assay tubes contained 
Sf9 membranes expressing either hCB1R and hCB2R (5 - 30 µg protein/tube),     
0.2% (m/v) bovine serum albumin, 3% (v/v) dimethyl sulfoxide, 1 nM [3H]CP 55,940, 
and varying concentrations of unlabeled CP 55,940 in 500 µl binding buffer (12.5 mM 
MgCl2, 1 mM EDTA, and 75 mM Tris/HCl, pH 7.4). For saturation binding assays and 
determination of Bmax values 10 nM [3H]CP 55,940 was used. Bovine serum albumin 
was added to prevent absorption of membrane protein to assay tubes. Non-specific 
binding was determined in the presence of 1 µM unlabeled CP 55,940. Incubations 
were conducted for 90 min at 25°C and shaking at 250 rpm on a platform shaker 
(InnovaTM 2000, New Brunswick Scientific, Edison, NJ, USA). Assays were stopped 
by filtration through GF/C filters soaked in 0.05% (m/v) polyethyleneimine, followed 
by three washes with 2 ml of ice-cold (4°C) binding buffer. Filter-bound 
[3H]CP 55,940 was determined by liquid scintillation with Rotiszint® eco plus cocktail 
(Roth Chemie, Karlsruhe, Germany) after at least 4 hours of equilibration at room 
temperature. Non-specific binding amounted to ~10% of total binding. 
 
Absolute agonist binding (pmoles of CP 55,940 bound per mg of membrane protein) 
was calculated as follows: 
 
[ ]
proteinmgaddedcpm
CPHpmolcnonspecificpmtotalcpm
mg
pmol
×
×−=
3)(
 
Equation 1 
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Explanations: 
cpm total: filter-bound radioactivity of [3H]CP 55,940 from assay tubes, 
except from those tubes containing 1 µM CP 55,940 
cpm non-specific: filter-bound radioactivity of [3H]CP 55,940 from assay tubes 
containing 1 µM CP 55,940 
pmol [3H]CP: absolute amount of [3H]CP 55,940 present in the assay tubes 
(0.5 pmoles in competition binding assays, 5.0 pmoles in 
saturation binding assays) 
cpm total added: the radioactivity of [3H]CP 55,940 added to each tube  
(no filtration) 
mg protein: absolute amount of membrane protein added per tube  
(0.005 – 0.030 mg) 
 
 
3.3.9 GTPγS binding assay 
 
The GTPγS binding assay was performed as described previously (Wenzel-Seifert et 
al., 1999; Wenzel-Seifert and Seifert, 2000; Seifert and Wenzel-Seifert, 2001). 
Briefly, membranes were thawed, sedimented by centrifugation at 18,000 x g for 
10 min at 4°C, and carefully resuspended in 10 mM Tris/HCl, pH 7.4. In GTPγS 
saturation binding experiments, assay tubes contained 0.2% (m/v) bovine serum 
albumin, 3% (v/v) dimethyl sulfoxide, 15 µg of membrane protein, 0.4 nM 
[35S]GTPγS, unlabeled GTPγS at various concentrations and 1 µM GDP in 500 µl 
binding buffer (12.5 mM MgCl2, 1 mM EDTA, and 75 mM Tris/HCl, pH 7.4) in the 
presence and absence of CBR ligands.  
For time course studies, Sf9 membranes (15 µg of protein/tube) were suspended in 
binding buffer supplemented with 0.2% (m/v) BSA, 3% (v/v) DMSO, 0.6 nM 
[35S]GTPγS plus 4.4 nM unlabeled GTPγS and 1 µM GDP in the presence and 
absence of CBR ligands (10 µM each). Aliquots of 200 µl were withdrawn at several 
time points.  
In GDP competition binding assays, the affinity of Gαi2 for GDP was determined in 
the presence of 0.2 nM [35S]GTPγS and varying concentrations of GDP ranging from 
1 nM to 10 µM in the absence or presence of 10 µM CP 55,940. Non-specific binding 
was taken as total binding in the presence of 10 µM unlabeled GDP and amounted to 
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less than 1% of total binding. Reactions were stopped by filtration through GF/C 
filters equilibrated with binding buffer. After filtration, filters were washed three times 
with 2 ml of ice-cold (4°C) binding buffer. Filter-bound radioactivity was determined 
by liquid scintillation counting in Rotiszint® eco plus cocktail after at least 4 hours of 
equilibration. 
 
Absolute ligand binding (pmoles of [35S]GTPγS bound per mg of membrane protein) 
was calculated as follows: 
 
[ ]
proteinmgaddedcpm
SGTPSpmolcnonspecificpmtotalcpm
mg
pmol
×
×−= γ
35)(  
Equation 2 
 
Explanations: 
cpm total: filter-bound radioactivity of [35S]GTPγS from assay tubes, except 
from those tubes containing 10 µM GTPγS 
cpm non-specific: filter-bound radioactivity of [35S]GTPγS from assay tubes 
containing 10 µM GTPγS  
pmol [35S]GTPγS: absolute amount of [35S]GTPγS present in the assay tubes, 
including any unlabeled GTPγS (0.2 pmoles in saturation binding 
assays, 2.5 pmoles in time course studies) 
cpm total added: the radioactivity of [35S]GTPγS added to each tube (no filtration) 
mg protein:  absolute amount of membrane protein added per tube  
(0.015 mg) 
3 Materials and Methods 
 
33
3.3.10 Steady-state GTPase assay 
 
The steady-state GTPase assay is an established approach to study G-protein 
coupling of GPCRs at a very proximal point of the signal transduction cascade. The 
GTPase assay was performed as described previously (Wenzel-Seifert et al., 1999). 
Membranes were thawed, sedimented by centrifugation at 18,000 x g for 10 min at 
4°C, and carefully resuspended in 10 mM Tris/HCl, pH 7.4. Assay tubes contained 
Sf9 membranes (15 µg of protein/tube), 1.0 mM MgCl2, 0.1 mM EDTA, 0.1 mM ATP, 
100 nM GTP, 0.1 mM adenylyl imidodiphosphate, 5 mM creatine phosphate, 40 µg of 
creatine kinase, 0.2% (w/v) bovine serum albumin in 50 mM Tris/HCl, pH 7.4, and 
CB1R and CB2R ligands at various concentrations. To determine the constitutive 
activity of hCBRs half of the assay tubes additionally contained 150 mM NaCl. 
Reaction mixtures (80 µl) were incubated for 2 min at 25°C before the addition of 
20 µl of [γ-32P]GTP (0.1 µCi/tube). All stock and work dilutions of [γ-32P]GTP were 
prepared in 20 mM Tris/HCl, pH 7.4. Reactions were conducted for 20 min at 25°C. 
Reactions were terminated by the addition of 900 µl of slurry consisting of 5% (w/v) 
activated charcoal and 50 mM NaH2PO4, pH 2.0. Charcoal absorbs nucleotides but 
not 32Pi. Charcoal-quenched reaction mixtures were centrifuged for 7 min at room 
temperature at 15,000 x g. Sixhundred µl supernatant fluid of reaction mixtures was 
removed, and 32Pi was determined by Čerenkov radiation in 3 ml water. Enzyme 
activities were corrected for spontaneous degradation of [γ-32P]GTP. Spontaneous  
[γ-32P]GTP degradation was determined in tubes containing all of the above 
described components plus a high concentration of unlabeled GTP (1 mM) that, by 
competition with [γ-32P]GTP, prevents [γ-32P]GTP hydrolysis by enzymatic activities 
present in Sf9 membranes. Spontaneous [γ-32P]GTP degradation amounted to <1% 
of the total amount of radioactivity added. The experimental conditions chosen 
ensured that not more than 10% of the total amount of [γ-32P]GTP added was 
converted to 32Pi. 
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GTPase activity (pmoles of Pi released per mg of membrane protein per min) was 
calculated as follows: 
 
proteinmgincubation minaddedcpm
unlabeledGTPpmolGTPcpmtotalcpm
minmg
pmol
××
××−=×
67.1)(  
Equation 3 
 
Explanations: 
cpm total: radioactivity of [γ-32P]GTP counted in the 600 µl aliquot taken 
from all assay tubes except those containing 1 mM GTP 
cpm GTP: radioactivity of [γ-32P]GTP counted in the 600 µl aliquot taken 
from the assay tubes containing 1 mM GTP 
pmol GTP 
unlabeled: absolute amount of substrate present in the assay tubes; i.e. with 
100 nM GTP, 10 pmoles of GTP were present in the 100 µl 
reaction mixture 
1.67: factor correcting the fact that only 600 µl out of 1000 µl in the 
assay tubes were counted 
cpm total added: the radioactivity of [γ-32P]GTP added to each tube (no charcoal 
addition) 
min incubation: assays were routinely conducted for 20 min 
mg protein:  absolute amount of membrane protein added per tube  
(0.015 mg) 
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3.3.11 AC assay 
 
AC assays were performed in order to determine the next step of the signaling 
cascade, after measuring the activation of Gα-subunits by steady-state GTPase and 
GTPγS binding assays. The AC assay was performed as described previously 
(Seifert et al., 1998). Briefly, Sf9 cell membranes coexpressing CBRs were thawed, 
sedimented by centrifugation at 18,000 x g for 10 min at 4°C, and resuspended in 
assay buffer (12.5 mM MgCl2 and 1 mM EDTA in 75 mM Tris/HCl, pH 7.4). Assay 
tubes contained Sf9 membranes (50 - 60 µg) and 10 µM GTP to activate Gαi2. 
Prestimulation of Gαi2 was obtained by addition of 10 µM or 100 µM forskolin. AC 
activity was determined under basal conditions (3% (v/v) DMSO served as control) or 
in the presence of CB1R and CB2R ligands (dissolved in 3% (v/v) DMSO). The final 
sample volume was 50 µl. Every assay tube contained 5 µl of ligand (10 µM final) or 
control and 5 µl of forskolin (10 µM or 100 µM final). To every tube 20 µl of a 
concentrated reaction mixture (2.5x) was added to obtain the following final 
concentrations: 0.2 – 0.3 µCi/tube of [α-32P]ATP, 40 µM of unlabeled ATP, 0.1 mM 
cAMP, 2.9 mM of mono(cyclohexyl)ammoniumphosphoenolpyruvate, 0.214 IU 
pyruvate kinase and 0.67 IU myokinase. Tubes were incubated for 2 min at 37°C, 
before starting the reactions by adding 20 µl homogenized membrane solutions in 
binding buffer. Reactions were carried out in hexaplicates at 37°C for 20 min and 
terminated by addition of 20 µl 2.2 N HCl. Denatured membrane protein was 
sedimented by a 1 min centrifugation step at room temperature and 15,000 x g. 
[32P]cAMP was separated from [α-32P]ATP by column chromatography. Columns 
were filled with 1.4 g of neutral alumina (MP Biomedicals, Eschwege, Germany). 
[32P]cAMP was eluted into 20 ml scintillation counting tubes by addition of 4 ml 0.1 M 
ammonium acetate solution, pH 7.0. [32P]cAMP was determined by Čerenkov 
radiation in water. Blank values were <0.01% of the total amount of [α-32P]ATP 
added and less than 0.1% of the total amount of [α-32P]ATP was converted to 
[32P]cAMP. 
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AC activity (pmoles of cAMP formed per mg of membrane protein per min) was 
calculated as follows: 
 
proteinmgincubationminaddedcpm
.unlabeledATPpmol)blankcpmtotalcpm(
minmg
pmol
××
××−=×
171  
Equation 4 
 
Explanations: 
cpm total: radioactivity of [32P]cAMP counted in the 50 µl aliquot analysed 
by column chromatography from all tubes except blank tubes 
cpm blank: radioactivity of [32P]cAMP counted in the 50 µl aliquot analysed 
by column chromatography from tubes containing no membranes 
pmol ATP 
unlabeled: absolute amount of substrate present in the assay tubes; i.e. with 
40 µM ATP, 2000 pmoles of ATP were present in the 50 µl 
reaction mixture 
1.17: factor correcting the fact that only 60 µl out of 70 µl in the assay 
tubes were counted 
cpm total added: the radioactivity of [α-32P]ATP added to each tube (no processing 
through alumina column) 
min incubation: assays were routinely conducted for 20 min 
mg protein: absolute amount of membrane protein added per tube  
(0.05 – 0.06 mg) 
 
 
3.3.12 Miscellaneous 
 
Experimental data were analysed by non-linear regression using the Prism 4.02 
program (GraphPad Software, San Diego, CA, USA). [3H]Dihydroalprenolol 
saturation binding was determined as described (Wenzel-Seifert and Seifert, 2000). 
Expression levels of recombinant proteins were determined using the BioRad       
GS-710 Calibrated Imaging Densitometer and the BioRad software tool Quantity One 
Version 4.0.3. 
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3.4 Phytochemical materials and methods 
 
3.4.1 Phytochemical materials 
 
Echinacea pallida roots were a kind gift by Martin Bauer (type nr.: 119966). Drug 
material was milled to powder (Retsch ZM1, Retsch, Haan, Germany) with a particle 
size smaller than 1.5 mm before extracting. All solvents for the extraction of the plant 
material were pure grade or purified by distillation prior to use.  
TLC analysis was done with Silica gel 60 RP-18 F254s aluminium sheets (Merck, 
Darmstadt, Germany). Bands were first detected by fluorescence extinction using an 
UV lamp at 254 nm, then by spraying 1% (m/v) vanillin in EtOH (96%) and 2% (v/v) 
H2SO4 (95-97%) and heating the plates at 110°C for 5 min. For vacuum liquid 
chromatography (VLC) Geduran Si 60 (63 – 200 µM) and for RP-18 column 
chromatography LiChroprep RP18 (40 – 63 µM) column material was used (Merck, 
Darmstadt, Germany). 
Dodeca-2E,4E-dienoic acid isobutylamide (2 mM (m/v) in DMSO) and Echinacea 
purpurea n-hexane root extract (10 mg/ml in DMSO) were a kind gift of Dr. J. 
Gertsch, ETH Zurich, Switzerland. 
Synthesized compounds were provided by M. Egger and P. Pellett, Institute for 
Organic Chemistry, Prof. B. König, University of Regensburg, Germany (for structure 
and name of the compounds see Table 2 and Fig. 13 and 14). 
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Table 2: Names of synthesized compounds tested in the GTPase assay.  
Bold names represent plant-derived compounds of E. pallida roots. 
 
 
 
 
 
Compound Name 
1 Pentadec-8Z-en-2-one 
2 Pentadeca-8Z,11Z-dien-2-one 
3 Tridec-8Z-en-12-yn-2-one 
4 Undec-8Z-en-10-yn-2-one 
5 Henicosa-6Z,9Z,12Z,15Z-tetraen-2-one 
6 8-Hydroxy-9,9-dimethyldecan-2-one 
7 2-Methyl-2-(tridec-6Z-enyl)-1,3-dioxolane 
8 2-Methyl-2-(trideca-6Z,9Z-dienyl-1,3- dioxolane 
9 2-Methyl-2-(pentadeca-6Z,9Z-dienyl-1,3-dioxolane 
10 2-Methyl-2-(non-6Z-ene-8-ynyl)-1,3-dioxolane 
11 Trimethyl(9-(2-methyl-1,3-dioxolan-2-yl)non-3Z-en-1-ynyl)silane 
12 2-Methyl-2-(9-phenylnon-6Z-en-8-ynyl)-1,3-dioxolane 
13 2-Methyl-2-(10-(2-methyl-1,3-dioxolan-2-yl)dec-4Z-en-6-ynyl)-1,3-dioxolane
14 11-Phenylundec-8Z-en-10-yn-2-one 
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Fig. 13: Structures of synthesized compounds (1 - 8) tested in the GTPase assay. 
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Fig. 14: Structures of synthesized compounds (9 - 14) tested in the GTPase assay. 
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3.4.2 Phytochemical methods 
 
300 g of milled E. pallida roots were extracted by accelerated solvent extraction 
(ASE 100, Dionex, Idstein, Germany) with n-hexane yielding in 1.5 g n-hexane 
extract (0.5% (m/m) yield). The ratio of milled E. pallida roots to sea sand was 4:1. 
Extraction was performed at 50°C in 50 ml cells. Two static circles were done, flush 
volume was 60%, purge time was 200 seconds and static time was 5 min. 
1.4 g of the n-hexane extract was subjected to vacuum liquid chromatography (VLC) 
on silica gel. The ratio of n-hexane extract to stationary phase was 1:90 (column 
length: 29.0 cm, diameter: 4.5 cm, height of the stationary phase: 17.0 cm). Seven 
different mobile phases (2 x 200 ml) with decreasing lipophilic properties were used 
to obtain a rough separation of the n-hexane extract (A: DCM, B: DCM : EtOAc 2:1, 
C: DCM : EtOAc 1:2, D: EtOAc, E: DCM : MeOH 2:1, F: DCM : MeOH 1:2, G: 
MeOH). The resulting 14 fractions after VLC (A1, A2, B1, etc.) were analysed by thin 
layer chromatography (TLC) and fractions with the same TLC profile were merged. 
Further separation of fractions containing alkenes or alkynes was done by RP-18 
column chromatography (CC) with a ratio of VLC fraction to stationary phase of 1:400 
(column length: 70.0 cm, diameter: 2.0 cm, height of the stationary phase: 34.5 cm). 
Fractions C, D, G obtained with DCM : EtOAc (1:2), EtOAc and MeOH did not 
contain alkenes or alkynes. Fraction A2 (DCM) was further separated by a mobile 
phase of ACN, MeOH and H2O in a ratio of 6:3:1. Fraction B (DCM : EtOAc 2:1), E 
(DCM : MeOH 2 : 1) and F (DCM : MeOH 1:2) were separated by a mobile phase of 
ACN, MeOH and H2O in a ratio of 2:1:1. The resulting fractions were analysed by 
TLC and fractions containing the same compounds were combined. Fractions 
containing multiple compounds were analysed by NMR spectroscopy for the 
presence of ketoalkenes or ketoalkynes. Those NMR spectra, which showed the 
functionalities of those compounds, were analysed in the functional GTPase assay. 
However, none of the fractions showed any activity in the GTPase assay, hence no 
further separation by HPLC was performed. 
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3.4.3 NMR spectroscopy and mass spectrometry 
 
All 1H NMR experiments were recorded in CDCl3 (Deutero, purity 99.8%) on a Bruker 
Avance 300 (operating at 300.13 MHz for 1H) at 300.0 K and referenced against 
residual non deuterated solvent. The 13C and 2D spectra for pentadec-8Z-en-2-one 
were measured on a Bruker Avance 400 (operating at 400.13 MHz for 1H and 100.61 
MHz for 13C) at 300.0 K in the same solvent. Coupling constants (J) were given in Hz. 
LREIMS (70 eV) was measured on a MAT 710A. 
 
 
3.4.4 Characterization of pentadec-8Z-en-2-one 
 
Colourless oil (31 mg). TLC (ACN : MeOH : H20 6 : 3 : 1.25) Rf = 0.26; 1H NMR 
(CDCl3, 300 MHz) δ 0.90 (3H, t, J = 6.0, CH3), 1.30 (12H, m overlapping signals, 6 x 
CH2), 1.55 (2H, m overlapping signals, CH2 ), 2.05 (4H, m overlapping signals, 2 x 
CH2), 2.12 (3H, s, COCH3), 2.47 (2H, t, J = 7.3, CH2CO), 5.34 (2H, m overlapping 
signals, HC=CH); 13C NMR (CDCl3, 75 MHz) 212.2 (CO), 131.1 (=CH), 130.6 (=CH), 
44.3 (CH2CO), 32.9 (CH2), 30.8 (CH2), 30.6 (CH2) 30.0 (CH3CO), 29.8 (CH2), 29.8 
(CH2), 28.1 (CH2), 28.0 (CH2), 24.8 (CH2), 23.7 (CH2), 14.4 (CH3); EI-MS (pos. mode) 
m/z 224 [M]
+
 (<1), 125 [M-C7H15]
+
 (10), 97 (13), 82 (16), 71 (29), 55 (33), 43 (100). 
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4 Results and Discussion 
 
4.1 Establishment of the steady-state GTPase assay as a functional 
test system for cannabinoid receptors 
 
4.1.1 Western blot analysis of cannabinoid receptors in Sf9 cell membranes 
 
To establish a functional test system for CBRs, Sf9 cells were transfected with 
baculoviruses encoding the CB1R or the CB2R. As Sf9 insect cells do not express 
mammalian G-proteins, baculoviruses encoding for Gα- and Gβγ-protein were used 
for cotransfection of CBR cell cultures. As we were interested in the most effective 
coexpression system, some CBR cultures were transfected additionally with 
baculoviruses encoding RGS4 or GAIP. 
All transfected cell cultures were harvested after 48 h incubation, the membranes 
expressing the receptor protein were prepared and hence analysed by 
immunoblotting. A representative immunoblot for the detection of CB1R-, CB2R-, 
Gαi2-, RGS4- and GAIP- protein is shown in Fig. 15. Membranes used in assays 
were generally analysed by immunoblots to ensure correct transfection. For further 
analysis of CBR membranes and expression levels see Chapter 4.3.1. 
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Fig. 15: Detection of expressed proteins in Sf9 cell membranes after transfection with 
baculoviruses encoding for CB1R, CB2R, Gαi2, RGS4 and GAIP. Numbers on the left 
indicate the apparent molecular mass of marker proteins in kDa. Each lane represents 10 µg 
of protein.  
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4.1.2 Solubility of cannabinoid receptor ligands 
 
Cannabinoid receptor ligands are highly lipophilic. Therefore, it is very important to 
dissolve them correctly. Commercially available stock solutions of CBR ligands are 
mostly prepared in 100% DMSO. The solvent DMSO can be used in concentrations 
up to 5% (v/v) without affecting receptor protein in Sf9 insect cell membranes. 
Initially, we prepared ligand solutions to achieve final DMSO concentration of 1% 
(v/v) in the experiments. However, in GTPase assays with ligand solutions containing 
1% (v/v) DMSO final, the obtained results were not consistent. This was due to 
solubility problems of the lipophilic compounds. By increasing the final DMSO content 
from 1% (v/v) to 3% (v/v) final in the assays, clear solutions as well as reliable and 
consistent GTPase activation could be observed (data not shown).  
Anandamide and ∆9-THC are presolved in ethanol because they are oily and no solid 
compounds. Evaporating the ethanol and dissolving the oily residue in DMSO to 
obtain 10 mM stock solutions is necessary for stability. 
 
 
4.1.3 Effect of different solvents on the solubility of CBR ligands assessed in 
the GTPase assay 
 
It was described that cannabinoid receptor ligand solutions should contain at least 
1 mg/ml BSA final to obtain stable solutions (Breivogel, 2006). Therefore, we 
compared the outcome of either 1 mg/ml BSA or 3% (v/v) DMSO in the functional 
GTPase assay.  
As our test system should be capable of detecting predominantly CB2R agonists, we 
compared 3 different agonists at both cannabinoid receptors (see Table 3 and     
Table 4). 
 
 
 
 
 
 
4 Results and Discussion 
 
45
For anandamide no differences could be found. Both solvents were equally effective 
on GTPase activation and logEC50 values were not affected. Regarding the agonist 
CP 55,940 the logEC50 value at CB1R was higher in BSA solutions (-8.36 ± 0.19 vs.   
-7.93 ± 0.06, p < 0.01). The GTPase stimulation was higher in solutions containing 
1 mg/ml BSA at CB2R (114 ± 5% vs. 94 ± 4%, p = 0.025). For WIN 55,212-2, the 
logEC50 value at CB1R was higher in solutions containing 3% (v/v) DMSO                 
(-7.38 ± 0.08 vs. -6.91 ± 0.05, p = 0.01). 
 
Taken these results together, both 3% (v/v) DMSO and 1 mg/ml BSA were suitable 
for the preparation of cannabinoid receptor ligand solutions and neither of them 
resulted in a pharmacological difference. GTPase stimulation as measured in the 
GTPase assay was reliable and reproducible for both solvents. Also, all obtained 
logEC50 values in this test system were in accordance with the values described in 
the literature.  
However, the addition of BSA causes foamy solutions after mixing, which may result 
in inaccuracies when small volumes are pipetted (e.g. 10 µl in the GTPase assay). 
Also, BSA tends to adsorb to plastic, which might decrease the actual BSA 
concentration in the solutions.  
The above described properties of BSA and the fact that most of the commercially 
available stock solutions are prepared in DMSO, led to the use of DMSO in a final 
concentration of 3% (v/v) DMSO for further experiments. 
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Table 3: Comparison of two solvents (1 mg/ml BSA and 3% (v/v) DMSO final) on 
GTPase activity of CB1R.  
Shown is the stimulation of GTPase activity by 10 µM agonist compared to basal (3% (v/v) 
DMSO) GTPase activity. Data were analysed by nonlinear regression and best fit to 
sigmoidal concentration/response curves. The results are expressed as percentages of 
mean values ± S.D. and represent 3 independent experiments performed in triplicates with 
different membrane preparations (* p = 0.01, ** p < 0.01). Literature data was published by 
Tocris Cookson (www.tocris.com). 
 
Table 4: Comparison of two solvents (1 mg/ml BSA and 3% (v/v) DMSO final) on 
GTPase activity of CB2R.  
Shown is the stimulation of GTPase activity by 10 µM agonist compared to basal (3% (v/v) 
DMSO) GTPase activity. Data were analysed by nonlinear regression and best fit to 
sigmoidal concentration/response curves. The results are expressed as percentages of 
mean values ± S.D. and represent n = 3 - 5 independent experiments performed in triplicates 
with different membrane preparations (* p = 0.025). Literature data was published by Tocris 
Cookson (www.tocris.com). 
 
Ligand CB1R + Gαi2 + 
Gβ1γ2 + RGS4 
GTPase 
stimul. [%] 
logEC50 logEC50 
(literature) 
Anandamide DMSO 80 ± 8 -6.80 ± 0.10 -7.10 
 BSA 73 ± 1 -6.64 ± 0.19  
CP 55,940 DMSO 63 ± 8 -7.93 ± 0.06** -8.30 
 BSA 71 ± 8 -8.36 ± 0.19**  
WIN 55,212-2 DMSO 69 ± 7 -7.38 ± 0.08* -7.20 
 BSA 87 ± 4 -6.91 ± 0.05*  
Ligand CB2R + Gαi2 + 
Gβ1γ2 + RGS4 
GTPase 
stimul. [%] 
logEC50 logEC50 
(literature) 
Anandamide DMSO 49 ± 6 -6.36 ± 0.44 -6.40 
n = 5 BSA 51 ± 6 -5.92 ± 0.16  
CP 55,940 DMSO 94 ± 4* -8.38 ± 0.10 -8.60 
n = 3 BSA 114 ± 5* -8.48 ± 0.09  
WIN 55,212-2 DMSO 95 ± 9 -8.59 ± 0.15 -8.50 
n = 3 BSA 89 ± 8 -8.37 ± 0.06  
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4.1.4 Evaluation of the influence of Gα-subunits (Gαo, Gαi2) and GTPase-
activating proteins (GAPs) on the GTPase activation of hCB1R and hCB2R 
 
As cannabinoid receptors are Gi/o-protein-coupled GPCRs, we compared the 
coexpression of Gαo- and Gαi2-subunits in Sf9 insect cells. We were further 
interested in the potential effects of GTPase-activating proteins (GAPs) on the 
GTPase activity stimulated by cannabinoid receptors. We chose to investigate the 
effect of two different GAPs, also named RGS-proteins (regulators of G-protein 
signaling-proteins), RGS4 and RGS19 (GAIP). 
Expression of the Gαo-subunit resulted in a low GTPase activation by 10 µM 
CP 55,940 (20 ± 6% for hCB1R and 27 ± 4% for hCB2R). The expression of Gαi2 
increased the GTPase activity to 53 ± 13% for hCB1R and 68 ± 5% for hCB2R (see 
Table 5). 
The effect of GTPase-activating proteins on GTPase activation was dependent of the 
coexpressed RGS-protein. Coexpression of CBRs and RGS4 was beneficial for all 
six constructs, with the highest increase in GTPase activity for membranes 
coexpressing Gαi2 and RGS4 (hCB1R: 70 ± 5%, hCB2R: 84 ± 7%). This increase in 
GTPase activation was statistically significant for the CB2R, comparing the Gαo/Gαi2 
+ Gβ1γ2 + RGS4 construct (p = 0.01). 
GAIP, the other investigated RGS-protein, only resulted in a stimulation of GTPase 
activity for the CB1R + Gαo + Gβ1γ2 construct (20 ± 6% vs. 49 ± 3%). For the other 
five constructs, the GTPase activation stayed at the same level as without RGS-
protein.  
logEC50 values were not statistically different for the CB1R analysing the 6 different 
membrane constructs. For the CB2R the logEC50 value for the Gαo + Gβ1γ2 construct 
was higher (p < 0.05) compared to the other membranes.  
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Table 5: Effect of Gα-subunits and RGS-proteins on GTPase activity.  
Shown is the stimulation of GTPase activity by CP 55,940 (10 µM) compared to basal 
(3% (v/v) DMSO) GTPase activity. Each membrane preparation contained additionally Gβ1γ2-
protein. Data were analysed by nonlinear regression and best fit to sigmoidal 
concentration/response curves. The results are expressed as percentages of mean values ± 
S.D. and represent n = 3 experiments for CB1R and n = 4 - 11 experiments for CB2R 
performed in triplicates with different membrane infections (* p < 0.05 for the logEC50 value 
CB2R + Gαo + Gβ1γ2 compared to the other five constructs, ** p = 0.01 for the GTPase 
activation by CB2R + Gαo/Gαi2 + Gβ1γ2 + RGS4). 
 
 
 
 
 
 
 
 
 
 
 
 hCB1R  hCB2R  
 
Membrane 
CP 55,940 
10 µM [%] 
 
logEC50 
CP 55,940 
10 µM [%] 
 
logEC50 
Gαo 20 ± 6 
n=3 
-7.45 ± 0.64 27 ± 4 
n=4 
-8.73 ± 0.14*  
Gαo + RGS4 67 ± 15  
n=3 
-7.81 ± 0.30 54 ± 8** 
n=6 
-8.38 ± 0.22 
Gαo + GAIP 49 ± 3 
n=3 
-7.74 ± 0.19 31 ± 5 
n=7 
-7.86 ± 0.17 
Gαi2 53 ± 13 
n=3 
-8.07 ± 0.05 68 ± 5 
n=10 
-8.29 ± 0.11 
Gαi2 + RGS4 70 ± 5 
n=3 
-8.01 ± 0.41 84 ± 7** 
n=11 
-8.11 ± 0.12 
Gαi2 + GAIP 55 ± 6 
n=3 
-8.02 ± 0.20 63 ± 5 
n=8 
-7.92 ± 0.29 
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At least 25 proteins with RGS domain are known, but they are highly diverse in their 
structure, expression levels and functions, e.g. not all RGS-proteins activate the 
GTPase function of Gα-subunits. RGS-proteins mainly interact with Gi- and Go-
proteins and accelerate the GTPase activity of Gα of the heterotrimeric G-protein by 
enhancing the cleavage of Pi. RGS4 and RGS19 (GAIP), which were used in our 
assays, belong to different classes of RGS-proteins. RGS4 is a small protein with no 
further functionalities than the RGS domain. GAIP also contains a cysteine string 
motif which may be palmitoylated and may improve membrane anchoring (Berman et 
al., 1996; Srinivasa et al., 1998; Traynor and Neubig, 2005). In general, RGS-
proteins act as “allosteric activators” at the Gα-GTP complex by facilitating the 
hydrolysis of GTP to GDP. If GTP is hydrolyzed the signal process is terminated. 
Hence, RGS-proteins increase the signal cascade by increasing the hydrolysis of 
GTP to GDP and Pi at the Gα-protein (Berman and Gilman, 1998). 
For cannabinoid receptors coexpressed with Gαo-protein, GTP hydrolysis apparently 
was the rate-limiting factor as coexpression of RGS4 increased the GTPase activity 
up to 3.5 fold at the Gαo-protein (CB1R: 20 ± 6%→ 67 ± 15%,                     
CB2R: 27 ± 4%→ 54 ± 8%). The effect was even more pronounced when CBRs were 
coexpressed with Gαi2 and RGS4 compared to Gαo without RGS4                     
(CB1R: 20 ± 6%→ 70 ± 5%, CB2R: 27 ± 4%→ 84 ± 7%), see Table 5. 
GAIP strongly activates Gαi3 and only weakly Gαi2 proteins (De Vries et al., 1995). 
This is in accordance to our findings in Table 5, where GAIP had no effect on Gαi2 
systems. It is known that a posttranslational processing and hence activation is 
necessary for GAIP. Sf9 insect cells may only perform an incomplete 
posttranslational processing, which was sufficient for activation of the CB1R + Gαo + 
Gβ1γ2 system but not for the CB2R + Gαo + Gβ1γ2 system. 
We did not observe a statistically significant effect of RGS-proteins on logEC50 
values, except for a higher logEC50 value coexpressing CB2R and Gαo without RGS-
proteins. Generally, RGS-proteins should not affect logEC50 values, because they 
only increase the intrinsic GTPase activity of Gα-subunits, but not the affinity of 
ligands for the receptor itself (Berman and Gilman, 1998). 
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4.2 Analysis of potencies and efficacies of agonists and 
antagonists/inverse agonists by steady-state GTPase assay 
 
The comparison of different Gα-proteins and different RGS-proteins showed that 
coexpression of Gαi2, Gβ1γ2 and RGS4 increased GTPase activity catalyzed by CBRs 
most efficiently (see Chapter 4.1.4). Hence, we chose this combination for further 
analysis of cannabinoid receptor ligands to assess the suitability of our test system. 
We compared a plant-derived agonist (∆9-THC), endogenous agonists (anandamide, 
2-AG), synthetic agonists (CP 55,940, WIN 55,212-2), as well as synthetic 
antagonists at CB1R (AM 251, AM 281) and at CB2R (AM 630), for results see 
Table 6.  
2-AG, the most abundant endogenous agonist, acted as a full agonist with similar 
potency at both CBRs. Emax values of all other ligands were related to the GTPase 
activation by 2-AG (Emax set 100%).  
∆9-THC acted as a partial agonist at CBRs, but had a higher efficacy at CB1R than 
CB2R (CB1R: 71 ± 5%, CB2R: 51 ± 11%). This finding was in accordance to literature 
(Felder and Glass, 1998; McPartland and Glass, 2003; Pertwee, 2008).  
Interestingly, AEA acted as a “superagonist” at CB1R (116 ± 19%) and as a partial 
agonist at CB2R (66 ± 15%). This higher efficacy of AEA at CB1R was statistically 
significant (p = 0.02) and in contrast to existing literature, where AEA behaved as a 
partial agonist at both CBRs (Zygmunt et al., 1999; Smart et al., 2000). 
Superagonism, a higher efficacy (Emax > 100%) than the endogenous most abundant 
ligand, has been already described for amthamine at canine H2R (Preuss et al., 
2007). 
At CB1R, CP 55,940 and WIN 55,212-2 were full agonists (91 ± 21% and 100 ± 17%) 
with EC50 values in the low nM range, which is in accordance to literature (Felder et 
al., 1995; Griffin et al., 1998). At CB2R, both CP 55,940 and WIN 55,212-2 were 
superagonists compared to 2-AG (118 ± 19% and 129 ± 21%). This result is in 
contrast to literature, where mostly no different efficacy of those ligands at CBRs was 
described (Rinaldi-Carmona et al., 1994; Felder et al., 1995). However, Song et al. 
showed that WIN 55,212-2 was more efficacious at CB2R and explained this finding 
by an amino acid residue change from valine in CB1R to phenylalanine in CB2R at 
position 46 in transmembrane helix 5 (Song et al., 1999). 
 
4 Results and Discussion 
 
51
AM 251 and AM 281 were described as selective CB1R antagonists with strong 
inverse agonist properties (Cosenza et al., 2000; Howlett et al., 2002). This finding 
was also demonstrated in our system, as AM 251 reduced GTPase acitivity by           
-83 ± 3% and AM 281 by -58 ± 2%. As AM 251 acted as a stronger inverse agonist at 
CBRs than AM 281, the Emax of GTPase inhibition by AM 251 was set -100%. Hence, 
AM 281 acted as a strong partial inverse agonist at CB1R (Emax -70 ± 2%). 
AM 630 behaved as a selective CB2R antagonist with only weak inverse agonistic 
behaviour by an inhibition of GTPase activity of only -25 ± 6%. The Emax value for 
AM 630 was also small with -30 ± 7% when related to the efficacy of AM 251. This 
finding is in accordance with the literature (Ross et al., 1999; Howlett et al., 2002). 
 
In summary, we compared agonists from 4 different classes of CBR ligands (classic: 
∆9-THC, non-classic: CP 55,940, aminoalkylindoles: WIN 55,212-2, eicosanoids: 
anandamide and 2-AG) as well as antagonists/inverse agonists at either CB1 or CB2 
receptors in the functional steady-state GTPase assay. In general, our findings agree 
with literature data. We revealed partial agonism at CBRs (∆9-THC), superagonism at 
CB1R (AEA), superagonism at CB2R (CP 55,940, WIN 55,212-2) as well as inverse 
agonism (AM 251, AM 281, AM 630).  
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Table 6: Analysis of different CBR ligands in the GTPase assay.  
Depicted is the stimulation by agonists or inhibition by antagonists of GTPase activity 
compared to basal GTPase activity, assessed by 3% (v/v) DMSO as control. Emax values 
represent the stimulation or inhibition relative to the endogenous agonist 2-AG (defined as 
100% response). Reaction mixtures contained CBR ligands at various concentrations  
(1 nM - 10 µM). Data were analysed by nonlinear regression and best fit to sigmoidal 
concentration/response curves. The results are expressed as mean values ± S.D. and 
represent 3 independent experiments performed with different membrane preparations. The 
efficacy of antagonists was determined in the presence of 3 nM CP 55,940. Data shown are 
the means ± S.D. of 3 independent experiments performed in triplicates. Anandamide had a 
higher efficacy at the CB1R (* p = 0.02). Literature data was published by Tocris Cookson 
(www.tocris.com). 
 
 
 
Ligand Gαi2 + 
Gβ1γ2  
+ RGS4 
GTPase 
stimulation / 
inhibition [%]
Emax 
[%] 
logEC50 / 
logIC50 
logEC50 / 
logIC50 
(literature)
∆9-THC hCB1R 49 ± 3 71 ± 5 -7.13 ± 0.14 -7.80 
 hCB2R 38 ± 5 51 ± 11 -6.77 ± 0.08 -6.50 
Anandamide hCB1R 80 ± 8* 116 ± 19 -6.80 ± 0.10 -7.05 
 hCB2R 49 ± 6* 66 ± 15 -6.36 ± 0.44 -6.40 
2-AG hCB1R 69 ± 6 100 -6.60 ± 0.12 -6.30 
 hCB2R 74 ± 25 100 -6.53 ± 0.51 -5.85 
CP 55,940 hCB1R 63 ± 8 91 ± 21 -7.93 ± 0.06 -8.30 
 hCB2R 87 ± 7 118 ± 19 -8.38 ± 0.11 -8.60 
WIN 55,212-2 hCB1R 69 ± 7 100 ± 17 -7.38 ± 0.08 -7.20 
 hCB2R 95 ± 9 129 ± 21 -8.59 ± 0.15 -8.50 
AM 251 hCB1R -83 ± 3 - 100 -7.11 ± 0.17 -8.10 
AM 281 hCB1R -58 ± 2  - 70 ± 2 -7.16 ± 0.11 -7.50 
AM 630 hCB2R -25 ± 6 - 30 ± 7 -7.86 ± 0.68 -7.50 
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4.3 Differences of CB1 and CB2 receptors 
 
4.3.1 Analysis of expression levels of hCBRs, Gαi2 and Gβ1γ2 in Sf9 membranes 
 
The predicted molecular mass of hCB1R is 55 kDa (Andersson et al., 2003; Xu et al., 
2005). Due to a shorter N-terminus the expected molecular mass for the hCB2R is 
only 40 kDa (Andersson et al., 2003; Filppula et al., 2004). We tagged hCBRs with 
an N-terminal FLAG epitope and a C-terminal hexahistidine epitope to facilitate 
immunological detection of GPCRs (Wenzel-Seifert et al., 1999; Wenzel-Seifert and 
Seifert, 2000; Seifert and Wenzel-Seifert, 2001). As expected, the M1 antibody, 
reacting with the FLAG epitope, detected a strong band at ~55 kDa for hCB1R and 
two bands at ~40 kDa for hCB2R (Fig. 16). The two hCB2R bands may reflect 
different glycosylation states. For hCB1R, additional weak bands at ~85 kDa and 
~140 kDa were detected by the M1 antibody. Those bands may reflect oligomeric 
forms of hCB1R. 
 
 
 
Fig. 16: Immunoblot analysis of hCBRs and Gαi2 in Sf9 cell membranes. For 
immunological detection and determination of the expression levels of receptors the M1 
antibody was used and for detection of Gαi2 the anti-Gαi common Ig was used. 
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To estimate the expression levels of hCBRs, a FLAG epitope-tagged β2AR 
expressed at 7.5 pmol/mg as assessed by [3H]dihydroalprenolol antagonist saturation 
binding was used (Wenzel-Seifert et al., 1999; Wenzel-Seifert and Seifert, 2000; 
Seifert and Wenzel-Seifert, 2001). Densitometric analysis revealed that in all 
membrane preparations studied, hCB1R was expressed at higher levels than hCB2R 
(Fig. 16 and Table 7). The overall hCBR expression levels in Sf9 membranes ranged 
between 3 – 7 pmol/mg and are comparable with the expression levels of other 
GPCRs in Sf9 membranes (Wenzel-Seifert et al., 1999; Wenzel-Seifert and Seifert, 
2000; Seifert and Wenzel-Seifert, 2001). 
In physiological systems, Gi-proteins are expressed at a 10 - 100-fold molar excess 
relative to GPCRs (Wenzel-Seifert et al., 1999; Wenzel-Seifert and Seifert, 2000; 
Seifert and Wenzel-Seifert, 2001). Therefore, in order to properly assess hCBR-
coupling to Gαi2β1γ2, it was important to ensure an appropriate GPCR/G-protein 
stoichiometry in Sf9 membranes. Purified Gαi protein with a molecular mass of      
~42 kDa (0.2-1.0 pmol/lane) was loaded onto gels, and the intensity of the bands was 
compared with the intensity of the Gαi2 bands in Sf9 membranes using the Gαi common 
antibody (Fig. 16). In fact, Gαi2 was highly expressed in Sf9 membranes, with levels 
ranging between ~200 – 350 pmol/mg protein (Table 7). Thus, Gαi2 expression levels 
exceeded hCBR expression levels by ~ 60-fold, ensuring a stoichiometry comparable 
to physiological systems. 
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However, for activation of GPCRs and forming the ternary complex Gβ1γ2-subunits 
have to be present. Therefore, to ensure that enough Gβ1γ2-subunits are available in 
Sf9 cell membranes, we determined the expression levels of Gβ1γ2 by loading 
purified Gβ1γ2 protein onto gels. Under blotting conditions, Gγ2 is uncoupled of Gβ1, 
hence we expect a molecular mass of ~ 36 kDa (Gβ1) on the gels (Sutkowski and 
Catterall, 1990). After detecting the bands with the Gβ common antibody (Fig. 17) the 
intensity of the bands in Sf9 cells was compared. Surprisingly, Gβ1γ2 was expressed 
at much lower levels than Gαi2 ranging between ~ 4 – 6 pmol/mg protein (Table 7).  
However, we show that the CBR/Gβ1γ2 ratio is approximately 1:1 ensuring a proper 
GPCR activation. 
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Fig. 17: Immunoblot analysis of Gβ1γ2 in Sf9 cell membranes. For immunological 
detection and determination of expression levels of Gβ1γ2 the anti-Gβ common Ig was used. 
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Table 7. Expression levels of hCBRs, Gαi2 and Gβ1γ2 in Sf9 membranes and 
stoichiometry of receptor/G-protein coupling. 
 
Parameter hCB1R + Gαi2 + Gβ1γ2 hCB2R + Gαi2 + Gβ1γ2 
Receptor expression level 
(pmol/mg)  
6.6 ± 0.9 3.4 ± 1.7 
Gαi2 expression level (pmol/mg) 370 ± 150 210 ± 140 
Gβ1γ2 expression level 
(pmol/mg) 
5.8 ± 1.2 4.3 ± 1.5 
GPCR/Gαi2 ratio 1 : 56 1 : 62 
GPCR/Gβ1γ2 ratio 1 : 1 1 : 0.8 
Bmax values 
(pmol/mg) 
16.4 ± 9.0 1.7 ± 0.9 
Ligand-regulated GTPγS binding 
(pmol/mg) 
5.3 ± 0.7 2.4 ± 1.1 
Expression levels for hCB1R and hCB2R were determined densitometrically as shown in    
Fig. 16 and Fig. 17 using FLAG epitope-tagged β2AR, purified Gαi2 and purified Gβ1γ2 protein 
as standard. Bmax values were determined by [3H]CP 55,940 saturation binding as described 
under Materials and Methods. Ligand-regulated GTPγS was determined as shown in Fig. 21 
in Chapter 4.3.3.3. Data shown are the means ± S.D. of experiments with 4 independent 
membrane preparations. 
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4.3.2 [3H]CP 55,940 competition and saturation binding 
 
Radioligand binding studies with the agonist [3H]CP 55,940 (Ross et al., 1999) were 
performed to confirm functional integrity of hCBRs. Using 1 nM [3H]CP 55,940 as 
tracer, unlabeled CP 55,940 inhibited radioligand binding to hCB1R with an IC50 of 
0.8 nM (95% confidence interval 0.6-1.0 nM) and to hCB2R with an IC50 of 0.8 nM as 
well (95% confidence interval 0.5-1.2 nM) (Fig. 18). These values fit very well to 
previously published data for hCBRs and confirm functional integrity of GPCRs 
(MacLennan et al., 1998; Filppula et al., 2004; Xu et al., 2005).  
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Fig. 18: [3H]CP 55,940 competition binding. Competition binding experiments were 
performed in Sf9 cell membranes expressing either hCB1R or hCB2R in presence of 1 nM 
[3H]CP 55,940. Total binding of [3H]CP 55,940 amounted to 2.3 ± 1.7 pmol/mg for hCB1R and 
to 0.5 ± 0.3 pmol/mg for hCB2R. Data were normalized, analysed by non-linear regression 
and best fit to a one-site (monophasic) competition curve. Data shown are the means ± S.D. 
of 6 experiments performed in triplicates with 3 different membrane preparations. 
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Saturation binding with 10 nM of the labeled agonist [3H]CP 55,940 was performed to 
determine the Bmax values of CBRs in Sf9 cells (see Table 7). Bmax values of the 
CB1R were much higher than estimated by densitometric analysis (16.4 ± 9.0 
pmol/mg protein vs. 6.6 ± 0.9 pmol/mg protein). It was the opposite for the CB2R, 
Bmax values assessed by saturation binding were lower than assumed by 
immunoblots (1.7 ± 0.9 pmol/mg protein vs. 3.4 ± 1.7 pmol/mg protein). These 
findings suggest, that for the CB1R high-affinity binding is possible without G-protein. 
In contrast, approximately half of the CB2R protein detected by immunoblots seems 
to be misfolded or misfunctioned.  
To address the question, if high-affinity binding without G-proteins exists for the 
CB1R, saturation binding assays in presence of 10 nM [3H]CP 55,940 and 10 µM 
GTPγS were performed. GTPγS binds to Gα, but can not be hydrolysed by the 
intrinsic GTPase activity of the Gα-subunit and leads to uncoupling of the receptor 
from the G-protein. Hence, Bmax values should be lower in presence of GTPγS. 
This was true for the CB2R, the presence of 10 µM GTPγS resulted in lower Bmax 
values (56.9 ± 20.1% of control). Just the opposite was true for the CB1R, the 
presence of 10 µM GTPγS resulted in Bmax values comparable to those without 
GTPγS (97.4 ± 18.9% of control). It can be concluded, that high-affinity binding at the 
CB1R is almost independent from G-protein binding. In contrast, the CB2R possesses       
G-protein independent binding, but to a much lower extent than the CB1R. 
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4.3.3 GTPγS binding studies 
 
The hydrolysis-resistant GTP analog [35S]GTPγS has been used to monitor the 
kinetics of GPCR/Gi-protein interaction and the stoichiometry of GPCR/G-protein 
coupling (Wenzel-Seifert et al., 1999; Wenzel-Seifert and Seifert, 2000; Seifert and 
Wenzel-Seifert, 2001).  
 
4.3.3.1 GTPγS time course studies 
First, we studied the time course of GTPγS binding (Fig. 19). Overall, GTPγS binding 
in membranes expressing hCB1R proceeded much faster than in membranes 
expressing hCB2R. In membranes expressing hCB1R, GTPγS bound to Gαi2 in the 
absence of a ligand with a t1/2 of 1.0 ± 0.2 min. CP 55,940 increased the maximum 
extent of GTPγS binding without accelerating t1/2 (1.9 ± 0.3 min). In contrast, the 
inverse hCB1R agonist AM 251 (Shearman et al., 2003) decreased the maximum 
extent of GTPγS binding without largely affecting t1/2 (0.4 ± 0.3 min). In membranes 
expressing hCB2R GTPγS binding under basal conditions proceeded with a t1/2 of 
55.7 ± 18.4 min. CP 55,940 increased the maximum extent of GTPγS binding and 
decreased t1/2 to 30 ± 6.2 min. The inverse hCB2R agonist AM 630 (Ross et al., 
1999) decreased the maximum extent of GTPγS binding and increased t1/2 to 
151 ± 90 min.  
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Fig. 19: Time course of GTPγS binding. Time course experiments were performed in Sf9 
cells expressing either hCB1R or hCB2R in presence 0.6 nM [35S]GTPγS plus 4.4 nM 
unlabeled GTPγS and 1 µM GDP. Data were analysed by nonlinear regression and best fit to 
a one-site (monophasic) binding curve. hCB1R: ♦, basal; ■, 10 µM CP 55,940; ▼, 10 µM AM 
251. hCB2R: ♦, basal; ■, 10 µM CP 55,940; ▼, 10 µM AM 630. Data shown are the means ± 
S.D. of a representative experiment performed in triplicates. Similar data were obtained in 3 
independent experiments. 
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4.3.3.2 GDP competition binding studies 
In order to determine the GDP-affinity of Gαi2 in membranes expressing hCBRs, 
GDP competition binding experiments were performed (Fig. 20). GDP competes with 
[35S]GTPγS for binding to Gαi2 and, thereby, reduces radioligand binding (Breivogel 
et al., 1998). In membranes expressing hCB1R, GDP inhibited [35S]GTPγS binding 
with an IC50 of 190 nM (95% confidence interval 100-340 nM). Agonists decrease 
GDP-affinity of G-proteins and, as a result, shift the GDP competition curve to the 
right (Breivogel et al., 1998; Wenzel-Seifert et al., 1999; Wenzel-Seifert and Seifert, 
2000; Seifert and Wenzel-Seifert, 2001). In agreement with this concept, CP 55,940 
reduced the GDP-affinity of Gαi2 to 1.14 µM (95% confidence interval 0.71-1.82 µM). 
In membranes expressing hCB2R, Gαi2 exhibited a higher GDP-affinity (IC50, 58 nM; 
95% confidence interval, 41-83 nM) than in membranes expressing hCB1R. In 
membranes expressing hCB2R, CP 55,940 reduced GDP-affinity of Gαi2 to a lesser 
extent (IC50, 340 nM; 95% confidence interval, 190-610 nM) than in membranes 
expressing hCB1R. 
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Fig. 20: GDP competition binding assay. GDP competition binding experiments were 
performed in Sf9 cells expressing either hCB1R or hCB2R in the presence of 0.2 nM 
[35S]GTPγS and varying concentrations of GDP ranging from 1 nM to 10 µM. Data were 
analysed by nonlinear regression and best fit to a one-site (monophasic) competition curve. 
Data shown are the means ± S.D. of 3 experiments performed in triplicates. 
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4.3.3.3 Determination of Kd and Bmax values by GTPγS binding studies 
We also determined the Kd values of agonist-stimulated and inverse agonist-inhibited 
[35S]GTPγS binding and the Bmax values of binding in membranes expressing hCB1R 
and hCB2R (Fig. 21). The Kd of CP 55,940-stimulated GTPγS binding in membranes 
expressing hCB1R was 5.1 ± 3.3 nM; the corresponding value in membranes 
expressing hCB2R was 2.0 ± 1.6 nM. The inverse hCB1R agonist AM 251 reduced 
GTPγS affinity to a Kd value of 4.1 ± 0.9 nM; the Kd value of AM 630-inhibited GTPγS 
binding in membranes expressing hCB2R was 1.0 ± 0.5 nM. The absolute GTPγS 
binding values in membranes expressing hCB1R were considerably larger than in 
membranes expressing hCB2R. Additionally, the inhibitory effect of the inverse 
agonist in membranes expressing hCB1R was much larger (58.1% of ligand-
regulated GTPγS binding) than in membranes expressing hCB2R (23.8% of ligand-
regulated GTPγS binding).  
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Fig. 21: GTPγS saturation binding assays with agonists and inverse agonists. GTPγS 
binding assays with membranes expressing hCB1R and hCB2R were performed as described 
under Materials and Methods. Reaction mixtures contained 0.4 nM [35S]GTPγS plus 
unlabeled GTPγS to yield the final ligand concentrations given on the abscissa. Reaction 
mixtures contained solvent (basal), 10 µM CP 55,940 or 10 µM AM 251 (hCB1R) or 10 µM 
AM 630 (hCB2R). The differences between CP 55,940-stimulated GTPγS binding and basal 
GTPγS binding as well as the differences between basal GTPγS binding and GTPγS binding 
in the presence of AM 251 or AM 630 were calculated. Differences were analysed by 
nonlinear regression and best fit to a one-site (monophasic) binding curve. hCB1R: ■, effect 
of CP 55,940; ▲, effect of AM 251. hCB2R: ■, effect of CP 55,940; ▲, effect of AM 630. Data 
shown are the means ± S.D. of a representative experiment performed in triplicates. Similar 
data were obtained with 4 different membrane preparations. 
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We also performed GTPγS binding assays with 1.0 nM [35S]GTPγS and cold GTPγS 
concentrations ranging from 1.6 – 18.6 nM, i.e. much higher final GTPγS 
concentrations than usually applied (up to 9.8 pmoles), see Fig. 22. Interestingly, we 
observed a change in the pharmacological profile of CP 55,940. Under the present 
conditions, CP 55,940, a high-affinity agonist, showed inverse agonist properties at 
the CB1R (Fig. 22A). Statistically significance (p < 0.05) was demonstrated for a 
GTPγS concentration of 4.3 pmoles (see Fig. 22A). A switch in ligand profiles from 
inverse agonism to weak partial agonism has also been described for the Gs-coupled 
β2AR expressed in Sf9 cells (Seifert et al., 1999). This effect has also been described 
for various β1- and β2-AR ligands in HEK293S cells (Galandrin and Bouvier, 2006). 
This switch was not observed for AM 251 at the CB1R. The agonistic effect of 
CP 55,940 or the inverse agonistic effect of AM 630 at the CB2R was not visible any 
more under the present conditions (Fig. 22B). 
The calculated difference between [35S]GTPγS bound in the presence of AM 251 and 
[35S]GTPγS bound under basal conditions at the CB1R was ~ 10 pmol/mg protein, 
although only ~ 6 pmol/mg Gβ1γ2 was expressed in Sf9 cells. This may result of 
binding of insect cell Gβγ-proteins at the CB1R instead of mammalian Gβ1γ2-protein. 
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Fig. 22: Agonist/antagonist-switch observed for CP 55,940 at the CB1R, assessed by 
GTPγS saturation binding. GTPγS binding assays with membranes expressing hCB1R and 
hCB2R were performed as described under Materials and Methods. Reaction mixtures 
contained 1.0 nM [35S]GTPγS plus unlabeled GTPγS to yield the final ligand concentrations 
given on the abscissa. Reaction mixtures contained solvent (basal), 10 µM CP 55,940 or    
10 µM AM 251 (hCB1R) or 10 µM AM 630 (hCB2R). Data was analysed by nonlinear 
regression and best fit to a one-site (monophasic) binding curve. A, hCB1R. ■, effect of      
CP 55,940; ▼, basal; ▲, effect of AM 251. B, hCB2R. ■, effect of CP 55,940; ▼, basal;      
▲, effect of AM 630. Data shown are the means ± S.D. of three merged experiments 
performed in duplicates with different membrane preparations. t-Test analysis was performed 
in A to evaluate the statistical significance of the difference of ligand-stimulated binding and 
basal binding (* p < 0.05, ** p < 0.01, *** p < 0.001). 
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4.3.4 Steady-state GTPase activity assay 
 
The GTPase assay assesses GDP/GTP exchange with subsequent GTP hydrolysis 
under steady-state conditions (Seifert et al., 1999; Wenzel-Seifert et al., 1999). As 
was the case for GTPγS binding, the absolute GTPase activities were higher for 
hCB1R than hCB2R (Fig. 23 and Table 8). CP 55,940 stimulated GTP hydrolysis at 
hCB1R and hCB2R in a concentration-dependent manner, whereas the inverse 
agonists AM 251 and AM 630 decreased GTP hydrolysis concentration-dependently. 
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Fig. 23: Regulation of GTPase activity by CBR ligands and NaCl. GTPase activity in Sf9 
membranes expressing hCB1R and hCB2R was determined as described under Materials 
and Methods. Reaction mixtures contained solvent (control) or 150 mM NaCl in the presence 
of CBR ligands at various concentrations. hCB1R: ●, CP 55,940; ▼, AM 251; ■, CP 55,940 
plus 150 mM NaCl; ▲ AM 251 plus 150 mM NaCl. hCB2R: ●, CP 55,940; ▼, AM 630;          
■, CP 55,940 plus 150 mM NaCl; ▲ AM 630 plus 150 mM NaCl. Data were analysed by 
nonlinear regression and best fit to sigmoidal concentration/response curves. Data shown 
are the means ± S.D. of 3 independent experiments performed in triplicates. 
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Na+ ions act as allosteric inverse agonist at Gi-coupled GPCRs and stabilize the 
inactive (R) state, thereby reducing constitutive G-protein activation and inverse 
agonist effects while increasing agonist effects (Seifert and Wenzel-Seifert, 2001; 
Seifert and Wenzel-Seifert, 2002). In accordance with this paradigm, NaCl (150 mM) 
reduced basal GTP hydrolysis in membranes expressing hCB1R by ~50%. Moreover, 
NaCl reduced the inverse agonistic effect of AM 251 and increased the agonistic 
effect of CP 55,940 (see Fig. 23). In agreement with the GTPγS binding data (Fig. 21 
in Chapter 4.3.3.3) the inverse agonist effect at hCB2R in the GTPase assay was 
considerably smaller than the inverse agonist effect at hCB1R compared to the 
corresponding agonist effects. In marked contrast to hCB1R, NaCl did not reduce 
basal GTPase activity and the inverse agonist effect in membranes expressing 
hCB2R, i.e. this GPCR was Na+-resistant (see Fig. 23). 
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Table 8. Regulation of GTPase activity in Sf9 membranes expressing hCB1R 
and hCB2R by CBR ligands and NaCl.  
 
Parameter Control NaCl (150 mM) 
hCB1R   
EC50 CP 55,940 (nM) 19 (9.6-37) 44 (25-78) 
IC50 AM 251 (nM) 84 (49-144) 64 (25-156) 
∆ CP 55,940 
(pmol/mg/min) 
2.52 3.85 
∆ AM 251 (pmol/mg/min) 4.10 2.27 
Ligand-regulated GTP 
hydrolysis (pmol/mg/min) 
6.59 6.12 
Relative stimulatory effect 
of CP 55,940 (% of ligand-
regulated GTP hydrolysis) 
38.2 62.9 
Relative inhibitory effect of 
AM 251 (% of ligand-
regulated GTP hydrolysis) 
61.8 37.1 
   
hCB2R   
EC50 CP 55,940 (nM) 7.9 (4.3-15) 19 (12-31) 
IC50 AM 630 (nM) 125 (23-676) 313 (116-851) 
∆ CP 55,940 
(pmol/mg/min) 
1.32 1.59 
∆ AM 630 (pmol/mg/min) 0.50 0.77 
Ligand-regulated GTP 
hydrolysis (pmol/mg/min) 
1.82 2.33 
Relative stimulatory effect 
of CP 55,940 (% of ligand-
regulated GTP hydrolysis) 
72.7 66.9 
Relative inhibitory effect of 
AM 630 (% of ligand-
regulated GTP hydrolysis) 
27.3 33.1 
The GTPase data shown in Fig. 23 were used as the basis for the calculations shown in this 
Table. EC50 and IC50 values were calculated by non-linear regression analysis. Mean values 
and 95% confidence intervals are shown. The table also shows the absolute increases in 
GTP hydrolysis caused by the agonist CP 55,940 and the absolute decreases in GTP 
hydrolysis caused by the inverse agonists AM 251 and AM 630, respectively. The difference 
between agonist-stimulated and inverse agonist-inhibited GTP hydrolysis constitutes ligand-
regulated GTP hydrolysis. From those values, the relative stimulatory effects of agonists and 
the relative inhibitory effectof inverse agonists were calculated. 
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4.3.5 AC assay 
 
Gαi-activation of GPCRs is typically associated with an inhibition of AC activity and 
hence a reduction of generated cAMP. We therefore investigated the effect of CBR 
ligands on AC activity after pre-stimulating the Gαi2-subunit with either 10 µM or    
100 µM forskolin (Fig. 24). CP 55,940 as an agonist did not reduce forskolin-
stimulated AC activity resulting in a decreased formation of cAMP as expected.     
AM 251 and AM 630, as inverse agonists at the CB1R or respectively the CB2R, did 
not increase AC activity resulting in an increased concentration of cAMP. 
 
 
Fig. 24: Effect of CBR ligands on AC activity after stimulation with forskolin. AC activity 
in Sf9 membranes expressing hCB1R (A) and hCB2R (B) was determined as described under 
Materials and Methods. Reaction mixtures contained 3% (v/v) DMSO (control) or forskolin 
(10 µM and 100 µM) in the presence of 10 µM CBR ligands. White bars represent the 
control, dotted bars the effect of 10 µM CP 55,940 and striped bars the effect of 10 µM      
AM 251 (A) or 10 µM AM 630 (B). Data shown are the means ± S.D. of a representative 
experiment performed in hexaplicates. Similar data were obtained in a second experiment 
with different membrane preparations. 
 
Cannabinoid receptors are highly constitutive active, as shown in GTPγS binding 
assays (see Chapter 4.3.3) and in steady-state GTPase assays (see Chapter 4.3.4). 
However, after activation of Gαi-protein the signaling cascade does not seem to be 
transduced to an inhibition of adenylyl cyclases. Yet, other down-stream effects, such 
as phoshorylation of proteins via MAP kinases could be influenced. 
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4.4 Pharmacological analysis of the alkamide dodeca-2E,4E-dienoic 
acid isobutylamide and E. purpurea n-hexane extract  
 
Echinacea has been used as an immune-stimulatory plant since the 18th century by 
the Indians of North America (Bauer and Wagner, 1990). Today, preparations of      
E. purpurea, E. angustifolia and E. pallida are commonly used. Up to now, several 
compound classes have been discussed as the active principle of Echinacea, e.g. 
caffeic acid derivatives, polysaccharides/glycoproteins and alkamides.  
Just a few years ago, the effect of hydrophilic and hydrophobic compounds of 
E. purpurea has been investigated. Only the hydrophobic alkamides showed a 
significant stimulation of the phagocytic activity of alveolar macrophages in rats (Goel 
et al., 2002; Goel et al., 2002a). Interestingly, alkamides show structural similarity to 
the endogenous cannabinoid receptor agonist anandamide (see Fig. 25) and 
dodeca-2E,4E-dienoic acid isobutylamide has been described as a high-affinity 
agonist at CB2R (Raduner et al., 2006). However, the interaction of dodeca-2E,4E-
dienoic acid isobutylamide with CB2R was only determined in [3H]CP 55,940 
competition binding assays. As this assay is not a functional test system we were 
interested if the compound would show any agonism or inverse agonism at CBRs in 
the established functional GTPase assay.  
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O
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H
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Anandamide      Dodeca-2E,4E-dienoic  
acid isobutylamide 
Fig. 25: Structures of the endogenous agonist anandamide and dodeca-2E,4E-dienoic 
acid isobutylamide. The alkamide dodeca-2E,4E-dienoic acid isobutylamide has been 
described as a CB2R agonist (Raduner, 2006). 
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4.4.1 [3H]CP 55,940 competition binding of dodeca-2E,4E-dienoic acid 
isobutylamide  
 
First, we analysed the alkamide dodeca-2E,4E-dienoic acid isobutylamide in 
competition binding assays at CBRs in the presence of 1 nM [3H]CP 55,940.  
A 2 mM stock solution of dodeca-2E,4E-dienoic acid isobutylamide in 100% (m/v) 
DMSO was dissolved to solutions containing final 3% (v/v) DMSO (1 nM - 10 µM). 
Unlabeled CP 55,940 (1 nM - 10 µM) was used as a positive control.  
A representative competition binding experiment for the CB2R is depicted in Fig. 26. 
Unlabeled CP 55,940 potently displaced labeled [3H]CP 55,940 at CB2R expressed in 
Sf9 cells (Ki = 6.6 nM), which was comparable to obtained data described in Chapter 
4.3.2. However, dodeca-2E,4E-dienoic acid isobutylamide did not displace the 
labeled [3H]CP 55,940 at the CB2R. This finding was surprising, as the alkamide has 
been reported as CB2R agonist determined by competition binding (Raduner et al., 
2006). We also analysed dodeca-2E,4E-dienoic acid isobutylamide at the CB1R, but 
again no displacement of [3H]CP 55,940 could be observed (data not shown). 
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Fig. 26: [3H]CP 55,940 competition binding of dodeca-2E,4E-dienoic acid 
isobutylamide. Data depicts a representative competition binding experiment obtained for 
CP 55,940 (■) and dodeca-2E,4E-dienoic acid isobutylamide (▲) in Sf9 cell membranes 
coexpressing CB2R, Gαi2, Gβ1γ2 and RGS4. 
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4.4.2 Analysis of dodeca-2E,4E-dienoic acid isobutylamide and E. purpurea 
extract in the GTPase assay 
 
In general, the analysis of compounds in competition binding assays is not useful for 
assessing pharmacological efficacy, e.g. agonism and inverse agonism. Hence, we 
decided to analyse the alkamide dodeca-2E,4E-dienoic acid isobutylamide and the  
n-hexane E. purpurea root extract in the functional GTPase assay. 
The 2 mM stock solution of dodeca-2E,4E-dienoic acid isobutylamide in 100% (m/v) 
DMSO was dissolved to solutions containing final 3% (v/v) DMSO. The compound 
was analysed for GTPase activation in a concentration range from 1 nM to 10 µM.  
For the establishment of the functional GTPase assay different Gα-subunits and 
different RGS-proteins were coexpressed with either CB1R or CB2R. The most 
efficient system to measure agonist activity at CBRs was CBxR + Gαi2 + Gβ1γ2 + 
RGS4 (see Chapter 4.1.4). We could also show that this coexpression was suitable 
for plant derived compounds, such as ∆9-THC (see Chapter 4.2). To ensure that this 
system is also the most appropriate system to detect ligands derived from Echinacea 
species, all six constructs were again analysed. Fig. 27 shows a representative graph 
for dodeca-2E,4E-dienoic acid isobutylamide at two different systems (CB2R + Gαi2 + 
Gβ1γ2 with and without RGS4). CP 55,940 (10 µM) was used as a positive control. 
The above described significant increase in GTPase activity by coexpression of 
RGS4 compared to membranes without RGS-protein could also be shown here for 
CP 55,940 (see Chapter 4.1.4). Coexpression of RGS4 resulted in an increase of 
GTPase activity of ~160% compared to ~80% when no RGS4 was present. However, 
the alkamide dodeca-2E,4E-dienoic acid isobutylamide failed to activate CB2R, even 
in micromolar concentrations. The same outcome was obtained for the other four 
CB2R coexpression systems. In addition, no effect at any of the six CB1R systems 
could be observed (data not shown).  
Analysing the n-hexane E. purpurea root extract (final concentrations 10 ng/ml – 
100 µg/ml) resulted in the same graph as depicted in Fig. 27. Again, 10 µM            
CP 55,940 as a positive control demonstrated the functionality of receptor protein, 
but the extract itself did not activate CBRs. 
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We also performed GTPase assays in the presence of 3 nM CP 55,940 (antagonist-
mode) to determine if the compound dodeca-2E,4E-dienoic acid isobutylamide or the 
n-hexane E. purpurea root extract act as antagonists at CBRs. Again, no effect was 
detected (data not shown). 
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Fig. 27: Effect of dodeca-2E,4E-dienoic acid isobutylamide on GTPase activity of the 
CB2R. Data depicts a representative result obtained in Sf9 cells expressing the CB2R and 
Gαi2 protein (▲), or the CB2R, Gαi2 and RGS4 proteins (■). All membranes contained 
additionally Gβ1γ2 protein. 10 µM CP 55,940 was used as a positive control for the CB2R and 
Gαi2 system (∆), or the CB2R, Gαi2 and RGS4 system (□). 
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4.4.3 Summary of the pharmacological analysis of dodeca-2E,4E-dienoic acid 
isobutylamide and E. purpurea extract 
 
An often discussed issue of alkamides is their low solubility in aqueous solutions due 
to their hydrophobic properties with a long alkyl chain and double bonds (Bauer and 
Wagner, 1990; Raduner et al., 2006; Raduner et al., 2007). For some alkamides the 
formation of micelles in aqueous solutions has been reported (Raduner et al., 2007). 
In the latter publication, the stock solution was prepared in 100% DMSO, yet no 
comment was made about the further content of DMSO in the assay tubes.  
 
Having performed extensive investigations on the solubility of commercially available 
CBR ligands (see Chapter 4.1.2 and 4.1.3), we describe for the first time that a 
DMSO content of 3% (v/v) is necessary for stable and clear CBR ligand solutions. 
Less than 3% (v/v) DMSO results in unstable and cloudy solutions, which cannot be 
used for reproducible experiments. As this analysis also included the endogenous 
agonists, anandamide and 2-AG, as well as the natural agonist, ∆9-THC, we assume 
that a content of 3% (v/v) DMSO is also necessary for the class of alkamides.  
We therefore suggest that data of alkamides obtained in aqueous solutions should be 
interpreted with caution. Unstable solutions may be the reason for the contradictory 
outcome in some publications or biphasic [3H]CP 55,940 competition binding assays 
(Raduner et al., 2006). Also, in the latter publication binding assays were performed 
without a positive control, e.g. CP 55,940.  
 
In general, we cannot confirm and explain the reported agonism of alkamides at 
CB2R. The alkamide dodeca-2E,4E-dienoic acid isobutylamide did neither displace 
[3H]CP 55,940 in competition binding assays nor did it show any activity in a 
functional test system. The GTPase assay would have detected not only agonism, 
but also inverse agonism or antagonism at CBRs. Another advantage of the GTPase 
assay is the point of measurement. We assessed ligand properties directly at the      
Gα-protein, namely at a very proximal point of the signal cascade of GPCRs. We also 
can rule out insufficient compound solubility, as depicted in Chapter 4.1.2 and 4.1.3. 
Furthermore, we assessed the functionality of receptor proteins by positive controls.  
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However, it is known that endocannabinoids are also ligands at other receptors, e.g. 
TRPV vanilloid receptors (Zygmunt et al., 1999; Smart et al., 2000). Also, some CBR 
ligands influence other target proteins, e.g. cyclooxygenases (Mestre et al., 2006). 
This may reflect the observed long-term effects of alkamides and E. purpurea 
preparations mediated by CBR-independent pathways (Beuscher et al., 1995; 
Melchart et al., 1998; Goel et al., 2002a; Hostettmann, 2003). 
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4.5 Pharmacological analysis of E. pallida root extract and its 
lipophilic compounds 
 
4.5.1 Isolation and characterization of pentadec-8Z-en-2-one 
 
Alkamides isolated from E. purpurea or E. angustifolia were previously described as 
CB2R agonists (Woelkart et al., 2005; Raduner et al., 2006). However, we show that 
neither the alkamide dodeca-2E,4E-dienoic acid isobutylamide nor the n-hexane 
extract of E. purpurea are ligands at CBRs (see Chapter 4.4). Interestingly, several 
Echinacea preparations contain only E. pallida. The latter shows ketoalkenes and 
ketoalkynes, a different class of compounds than in E. purpurea and E. angustifolia. 
To the best of our knowledge, the pharmacological effects of these compounds at 
CBRs have never been investigated. Therefore, we were interested if extracts of     
E. pallida or isolated compounds would be ligands at either CB1 or CB2 receptors.  
The extraction of E. pallida roots with ASE, followed by subsequent VLC and        
RP-18 CC of the VLC fraction A2 (DCM), resulted in the isolation of an oily, 
chemically pure main compound (31.0 mg). Its EIMS displayed a molecular ion at 
m/z 224 [M]+ indicating, together with the 13C NMR and DEPT data, a molecular 
formula of C15H28O (Chapter 3.4.3 and 3.4.4). The structure of the compound was 
elucidated by comprehensive 1D and 2D NMR analyses (1H, 13C NMR, HSQC and 
HMBC) and revealed the presence of pentadec-8Z-en-2-one (see Fig. 28). The 1H 
and 13C NMR data were presented in the experimental part (Chapter 3.4.4) and were 
identical to literature data (Dickschat et al., 2005). Identity of the isolate was finally 
confirmed by comparison to authentic reference compound in TLC system           
ACN : MeOH : H2O 6 : 3 : 1.25 (Rf = 0.26). 
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Fig. 28: Pentadec-8Z-en-2-one, a ketoalkene isolated of E. pallida roots. 
 
4 Results and Discussion 
 
77
Pentadec-8Z-en-2-one has been reported as one of the main ketoalkenes in the 
essential oil from roots of E. pallida (Bauer and Wagner, 1990), yet the yield of the 
isolated compound was relatively low. Unfortunately, the isolation of more 
compounds of E. pallida was not possible due to the small amount of starting 
material and the presence of multiple minor compounds. However, after CC on     
RP-18 material as stationary phase the fractions containing more than one 
compound were merged and analysed by 1H NMR spectroscopy. Fractions showing 
the functionalities of ketoalkenes or ketoalkynes (double bonds, alkyl chains and 
CH3CO) were analysed in the functional GTPase assay at CBRs. None of the 
obtained fractions showed activity and thus further bio-activity guided isolation of 
active ligands was not performed. 
 
 
4.5.2 Pharmacological evaluation of pentadec-8Z-en-2-one, fractions from CC 
on RP-18 material and n-hexane E. pallida root extract in the functional GTPase 
assay 
 
Pentadec-8Z-en-2-one was dissolved in 100% (m/v) DMSO to prepare a 10 mM 
stock solution. Then, the stock solution was diluted in a way that all following 
solutions contained 30% (v/v) DMSO (final 3% (v/v) DMSO in the assay). The final 
investigated concentrations ranged from 1 nM - 10 µM in the assay. We tested the 
isolated compound as well as RP-18 CC fractions at Sf9 insect cell systems 
coexpressing CBxR, Gαi2, Gβ1γ2 and RGS4. Among all studied systems, this 
construct yielded highest GTPase activation when the effect of the agonist CP 
55,940 was analysed (see Chapter 4.1.4). We could also show that this construct is 
suitable for plant derived compounds, such as ∆9-THC (see Chapter 4.2). CP 55,940 
and the endogenous agonist anandamide were used as positive controls to ensure 
the functionality of the expressed receptor protein (both 10 µM final). 
However, pentadec-8Z-en-2-one did neither activate the CB1R nor the CB2R in the 
functional GTPase assay. The experiment was repeated twice with different CB1R 
and CB2R membranes, but again, only the positive controls, CP 55,940 and AEA, did 
increase the GTPase activity at CBRs (data not shown). 
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Several fractions showed the presence of ketoalkenes and/or ketoalkynes in the 
recorded 1H NMR spectrums. Also, the crude n-hexane extract of E. pallida roots was 
analysed for CBR activation. Stock solutions of fractions and the n-hexane root 
extract (each 10 mg/ml) in DMSO were prepared and diluted to obtain solutions with 
3% (v/v) DMSO final. The analysed concentrations in the assay ranged from final 
1 ng/ml to 100 µg/ml. However, no activation of GTPase activity at CBRs by any 
fraction or the n-hexane extract of E. pallida roots could be detected. Experiments 
were repeated twice with different Sf9 cell membranes expressing either CB1R or 
CB2R.  
 
 
4.5.3 Summary of the pharmacological analysis of pentadec-8Z-en-2-one and 
E. pallida extract 
 
Several isolation steps (ASE, VLC, RP-18 CC) yielded one completely characterized 
ketoalkene of E. pallida. Extraction of plant material and isolation of compounds is 
very time- and solvent-consuming and yields only small amounts of compounds. To 
obtain more compounds or higher yields the extraction process has to be up-scaled 
to increase the efficacy of isolation of compounds of plant material. Several other 
fractions contained ketoalkenes after NMR spectroscopy and functional testing in the 
GTPase assay was performed before separating the compounds by HPLC. However, 
neither the isolated ketoalkene pentadec-8Z-en-2-one nor the analysed RP-18 CC 
fractions nor the n-hexane E. pallida root extract did activate CBRs.  
4 Results and Discussion 
 
79
4.6 Pharmacological analysis of synthesized constituents of           
E. pallida roots 
 
Cannabinoid receptor agonists can be divided in 4 structural classes. First, the 
classic cannabinoids, e.g. ∆9-THC, isolated from C. sativa. Second, the non-classic 
cannabinoids, e.g. CP 55,940, a Pfizer compound derived from ∆9-THC. In the third 
class are the endogenous cannabinoids, e.g. anandamide or 2-AG and in the fourth 
class are the aminoalkylindoles, e.g. WIN 55,212-2. Members of the Department of 
Organic Chemistry at the University of Regensburg synthesized 14 compounds (for 
structures and names see Table 2, Fig. 13A and 13B in Chapter 3.4.1). The 
compounds were plant-derived ketoalkenes (compound 1 and 2) or non-plant-derived 
ketoalkenes (compound 3 and 4). Compound 1 was identical with the isolated 
compound of E. pallida, as described in Chapter 4.5.1. One compound (5) was a 
derivative of the third class, the endogenous cannabinoids. Most of the synthesized 
compounds were derivated ketoalkenes (compounds 6 - 14). 
Coexpression of CBxR, Gαi2, Gβ1γ2 and RGS4 yielded the highest GTPase activation 
in Sf9 cells (see Chapter 4.1.4). Hence, this system was chosen for the analysis of 
the agonistic, inverse agonistic or antagonistic potential of the synthesized 
compounds in the functional GTPase assay. The effect of 2-AG, the most abundant 
endogenous ligand at CBRs, was defined as 100% stimulation.  
Yet, none of the synthesized natural ketoalkenes (1, pentadec-8Z-en-2-one or 2, 
pentadeca-8Z,11Z-diene-2-one) resulted in an activation of GTPase activity. This is 
in accordance with our findings in Chapter 4.5.2, where the isolated compound 1, 
several fractions and the n-hexane extract of E. pallida were investigated. However, 
three of the synthesized compounds acted as agonists at CBRs in the GTPase assay 
(see Fig. 29 and Table 9). 
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Fig. 29: Structure of anandamide and of synthesized compounds that are 
agonists at CBRs in the functional GTPase assay. 
 
 
Compound 5, henicosa-6Z,9Z,12Z,15Z-tetraen-2-one, was a full agonist at CB1R 
(Emax: 99 ± 9%) and a superagonist at CB2R (Emax: 114 ± 9%). This was not 
surprising, as compound 5 is very similar to the endogenous agonist anandamide by 
replacing the isobutyl amine at the keto functionality with a methyl group (see Fig. 
29). This substitution even led to a much higher efficacy at the CB2R compared to the 
endogenous ligand anandamide (Emax value 114 ± 9% vs. 66 ± 15%). However, the 
logEC50 values of compound 5 were only in the micromolar range (CB1R:                   
-5.71 ± 0.44; CB2R: -5.46 ± 0.29) compared to anandamide (CB1R: -6.80 ± 0.10; 
CB2R: -6.36 ± 0.44) or 2-AG (CB1R: -6.60 ± 0.12; CB2R: -6.53 ± 0.51). This finding 
suggests that substitution of the carboxy group at C1 with a larger or an amine-
containing group, e.g. ethanolamine (anandamide) or glycerol (2-AG) is necessary 
for a high affinity at CBRs.  
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Compound 12 (2-methyl-2-(9-phenylnon-6Z-en-8-ynyl)-1,3-dioxolane) and compound 
14 (11-phenylundec-8Z-en-10-yn-2-one) were derived from natural ketoalkenynes of 
Echinacea species with a keto group at C2, a cis-double bond at C8 and a triple bond 
at C10. In compound 14, substitution of the terminal methyl group by a benzyl moiety 
led to partial agonism at both CBRs (Emax at CB1R: 59 ± 35%, Emax at CB2R: 
59 ± 18%) with an affinity in the micromolar range. Protecting the keto group at C2 
and substitution at C11 by a benzyl moiety (compound 12) resulted in a low efficacy 
at the CB1R (Emax: 21 ± 22%) and partial agonism at the CB2R (Emax: 45 ± 6%). The 
affinity of compound 12 for CBRs also was in the micromolar range (logEC50 at 
CB1R: -5.66 ± 0.16, logEC50 at CB2R: -5.23 ± 0.62). 
 
Hence, we identified novel agonists at CBRs derived from natural ketoalkenynes of 
Echinacea as assessed by the GTPase assay. However, the affinity of the 
compounds at CBRs has to be improved in future studies.  
 
 
Table 9: Activation of GTPase activity, Emax values and logEC50 values of 2-AG, 
anandamide (AEA) and synthesized compounds 5, 12 and 14.  
 
 CB1R + Gαi2 + Gβ1γ2 + RGS4 CB2R + Gαi2 + Gβ1γ2 + RGS4 
 GTPase 
activation 
[%] 
Emax [%] logEC50 GTPase 
activation  
[%] 
Emax [%] logEC50 
2-AG 69 ± 6 100 -6.60 ± 0.12 74 ± 25 100 -6.53 ± 0.51 
AEA 80 ± 8 116 ± 19 -6.80 ± 0.10 49 ± 6 66 ± 15 -6.36 ± 0.44 
5 68 ± 6 99 ± 9 -5.71 ± 0.44 85 ± 7 114 ± 9 -5.46 ± 0.29 
12 15 ± 11a 21 ± 22a -5.66 ± 0.16a 33 ± 3 45 ± 6 -5.23 ± 0.62 
14 41 ± 20 59 ± 35 -5.28 ± 0.27 44 ± 11 59 ± 18 -5.84 ± 0.19 
Results are expressed as percentages of mean values ± S.D. compared to basal GTPase 
activation assessed by 3% (v/v) DMSO. Emax values represent the stimulation relative to the 
endogenous agonist 2-AG (defined as 100% stimulation). Data represents 3 independent 
experiments (a represents 2 experiments) performed with different membrane preparations. 
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5 Conclusion and Outlook 
 
5.1 Pharmacological test systems for cannabinoid receptors 
 
We established several test systems for cannabinoid receptors using the Sf9 
cell/baculovirus transfection system. Sf9 cells offer several advantages to study the 
function of GPCRs. They are easy to grow and yield high expression levels of 
GPCRs and G-proteins. Furthermore, Sf9 cells do not express mammalian              
G-proteins leading to excellent signal-to-noise ratios in experiments. 
We investigated the solubility of cannabinoid receptor ligands and show for the first 
time that a final DMSO assay concentration of 3% (v/v) is necessary for stable 
solutions. Also, we describe that BSA as a solvent has no advantage over DMSO.  
Furthermore, we were interested if different Gα- and RGS-proteins influence GTPase 
activation. We found that coexpression of cannabinoid receptors with Gαi2, Gβ1γ2 and 
RGS4 yielded the most effective system.  
We also performed [3H]CP 55,940 competition binding assays to identify new ligands 
at CBRs. The establishment of GTPγS binding assays and functional GTPase assays 
allows for the detection of agonists, partial agonists, inverse agonists and antagonists 
at a very proximal point of the signal cascade of GPCRs. 
Further studies should evaluate the effect of other RGS-proteins at Gαo-, Gαi2- or 
other G-protein subtypes. It would also be of high interest to evaluate the potencies 
of CBR ligands in mammalian cell lines stably transfected with CBRs. 
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5.2 Differential coupling of cannabinoid receptors to G-proteins 
 
We were also interested in pharmacological properties of CBRs and decided to focus 
on the differential coupling of CBRs to Gαi2-proteins.  
The expression levels of CB1R were approximately two-fold higher than those of 
CB2R. This led to higher Bmax values for the CB1R in [3H]CP 55,940 competition 
binding and GTPγS binding assays. GTPγS time course binding studies revealed a 
much faster activation of the CB1R after ligand binding. Compared to CB2R, CB1R 
possesses a higher constitutive activity, as assessed in GTPγS saturation binding 
and in GTPase assays in the presence of NaCl. For the agonist CP 55,940, we also 
describe for the first time an agonist / inverse agonist switch at CB1R. 
Further studies should investigate other ligands for possible changes in their 
pharmacological properties, which may depend on assay conditions. Also the 
coupling of CBRs to Gαo-proteins needs to be evaluated in greater detail.  
 
 
5.3 Alkamides of E. purpurea– agonists at CB2R? 
 
After the establishment of several test systems for CBRs, we reviewed the 
hypothesis that alkamides from E. purpurea are CB2R agonists.  
Although anandamide and 2-AG do possess a very similar structure compared to 
alkamides, our findings do not support the literature where alkamides have been 
described as CB2R ligands. Solubility problems of alkamides due to their amphiphilic 
structure seem reasonable and micelle formation has been described (Raduner et 
al., 2007). However, we can rule out insufficient compound solubility, having 
performed extensive solubility experiments with CBR ligands. Also, the hypothesis 
that alkamides are high-affinity agonists at CB2R in the nanomolar range has been 
reported by only one research group.  
We always assessed the functionality of receptor proteins. Furthermore, we analysed 
the alkamide dodeca-2E,4E-dienoic acid isobutylamide not only in a competition 
binding assay, but also in a functional assay at a very proximal point of the signal 
cascade of GPRCs. 
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However, the immunomodulatory effects of alkamides and Echinacea preparations 
cannot be explained by activation of cannabinoid receptors. Long-term effects of 
Echinacea preparations may be mediated by different target proteins.  
 
 
5.4 Ketoalkenes and ketoalkynes of E. pallida – the active principle 
of Echinacea? 
 
For the first time, isolated and synthesized compounds as well as a n-hexane extract 
derived from E. pallida were analysed for affinity at cannabinoid receptors.  
The investigated plant-derived compounds of E. pallida are not ligands at 
cannabinoid receptors. However, we describe new synthesized ligands at CBRs.      
A compound derived from the endogenous agonists, anandamide and 2-AG, is a full 
agonist at CB1R and a superagonist at CB2R. Also, two more compounds derived 
from natural ketoalkenynes show partial agonism at CBRs. 
 
Although ketoalkenes and ketoalkynes of E. pallida do not show any CBR-affinity, 
three synthesized compounds derived from ketoalkenynes are ligands at CBRs. 
Further studies should include structure-activity-relationship investigations to obtain 
compounds with higher affinities at CBRs. 
6 Abstracts and Publications 
 
85
6 Abstracts and Publications 
 
Prior to submission of this thesis, results were in part published or were presented as 
posters or short lectures. 
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